1
Status: Approved ,Date: 15 December 2017Janssen Research & Development , LLC *
Clinical Protocol
A Phase 2b, Multicenter, Double -masked, Randomized S tudy E valuating the S afety and 
Clinical Response of Subretinal A dministration of CNTO 2476 in Subjects with V isual 
Acuity I mpairment Associated with Geographic Atrophy Secondary to Age Related 
Macular Degeneration
Protocol CNTO2476MDG2002 ; Phase 2b
AMENDMENT 3
CNTO 2476
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, In c.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Ireland UC; or Janssen Research & 
Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal 
entities; the sponsor is identified on the Contact Information page that accompanies the protocol.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
Status: Approved
Date: 15 December 2017
Prepared by: Janssen Research & Development, LLC
EDMS number :EDMS- ERI-95495761, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information i s disclosed must be informed that the information is privileged or confidential and may not be further disclosed by 
them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confi dential.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
2
Status: Approved , Date: 15 December 2017TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF A TTACHMENTS ............................................................................................................................ 4
LIST OF IN -TEXT T ABLES A ND FIGU RES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 17
TIME AND EVENTS SCHE DULES ............................................................................................................ 25
ABBREVIA TIONS ...................................................................................................................................... 28
1. INTRODUCTION ................................................................................................................................ 30
1.1. Background .................................................................................................................................... 31
1.1.1. Nonclinical Studies ..................................................................................................................... 31
1.1.1.1. Mechanism of Action ............................................................................................................... 31
1.1.1.2. Pharmacokinetic Profile ........................................................................................................... 31
1.1.1.3. Immunogenicity ....................................................................................................................... 32
1.1.1.4. Toxicology ................................................................................................................................ 32
1.1.2. Clinical Studies ........................................................................................................................... 33
1.1.2.1. Human Pharmacokinetics ........................................................................................................ 33
1.1.2.2. Efficacy .................................................................................................................................... 33
1.1.2.3. Safety ....................................................................................................................................... 34
1.2. Overall Rationale for hUTC Development and Deliver y System Innovation .................................. 36
1.3. The Cell Deliv ery System ............................................................................................................... 37
2. OBJECTIVES A ND HYPOT HESES .................................................................................................. 37
2.1. Objectives ...................................................................................................................................... 37
2.2. Hypothesis ..................................................................................................................................... 38
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .38
3.1. Overview of Study Design .............................................................................................................. 38
3.2. Study Design Rationale .................................................................................................................. 40
3.2.1. Control ........................................................................................................................................ 41
3.2.2. Masking ....................................................................................................................................... 41
3.2.3. Randomization ............................................................................................................................ 41
3.2.4. Primary Outcome Measure ......................................................................................................... 41
4. SUBJECT POPUL ATION.................................................................................................................. 41
4.1. Inclusion Criteria ............................................................................................................................ 41
4.2. Exclusion Criteria ........................................................................................................................... 43
4.3. Prohibitions and Restrictions ......................................................................................................... 46
5. TREA TMENT A LLOCA TION AND M ASK ING................................................................................. 46
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 46
6.1. Open -label Safety Run -in Phase ................................................................................................... 46
7. TREA TMENT COMPLIA NCE ............................................................................................................ 47
8. PRESTUDY A ND CONCOMI TANT THERA PY................................................................................ 47
9. STUDY EVA LUATIONS .................................................................................................................... 48
9.1. Study Procedures ........................................................................................................................... 48
9.1.1. Overview ..................................................................................................................................... 48
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
3
Status: Approved , Date: 15 December 20179.1.1.1. Screening Phase ..................................................................................................................... 49
9.1.1.2. Open -label Safety Run -in Phase ............................................................................................. 51
9.1.1.3. End of Treatment or Early W ithdrawal .................................................................................... 51
9.1.1.4. Long- term Follow -up Phase .................................................................................................... 51
9.2. Efficacy ........................................................................................................................................... 51
9.2.1. Evaluations ................................................................................................................................ .51
9.2.1.1. Primary Efficacy  Measure ........................................................................................................ 51
9.2.1.2. Secondary Efficacy Measures ................................................................................................ .52
9.2.2. Endpoints .................................................................................................................................... 52
9.3. Immunogenicity .............................................................................................................................. 52
9.3.1. Evaluations ................................................................................................................................ .52
9.3.2. Analytical Procedures ................................................................................................................. 53
9.3.3. Immunogenicity Assessments .................................................................................................... 53
9.4. Intraoperative Deliver y System and Procedure Evaluations .......................................................... 53
9.5. Safety Evaluations ......................................................................................................................... 53
9.5.1. Adverse Events ........................................................................................................................... 53
9.5.2. Clinical Laboratory Tests ............................................................................................................ 54
9.5.3. Vital Signs ................................................................................................................................... 55
9.5.4. Physical Examination .................................................................................................................. 55
9.6. Sample Collection and Handling .................................................................................................... 55
10. SUBJECT COMPLETION/W ITHDRA WAL....................................................................................... 55
10.1. Completion ..................................................................................................................................... 55
10.2. Discontinuation/W ithdrawal from the Study ................................................................................... 55
11. STATISTICA L METHODS ................................................................................................................. 56
11.1. Subject Information ........................................................................................................................ 56
11.2. Sample Size Determination ........................................................................................................... 57
11.3. Efficacy  Analyses ........................................................................................................................... 57
11.4. Immunogenicity Analyses .............................................................................................................. 57
11.5. Safety Analyses ............................................................................................................................. 57
11.6. Data and Safety Monitoring Board ................................................................................................ .58
12. ADVERSE EVENT REPORT ING...................................................................................................... 59
12.1. Definitions ...................................................................................................................................... 59
12.1.1. Adverse Event Definitions and Classifications ........................................................................... 59
12.1.2. Attribution Definitions .................................................................................................................. 60
12.1.3. Severity Criteria .......................................................................................................................... 61
12.2. Special Reporting Situations .......................................................................................................... 61
12.3. Procedures ..................................................................................................................................... 62
12.3.1. All Adverse Events ...................................................................................................................... 62
12.3.2. Serious Adverse Events ............................................................................................................. 63
12.4. Contacting Sponsor Regarding Safety ........................................................................................... 63
13. PRODUCT QUA LITY COMP LAINT HA NDLING .............................................................................. 64
13.1. Procedures ..................................................................................................................................... 64
13.2. Contacting Sponsor Regarding Product Quality ............................................................................ 64
14. TREA TMENT INFORM ATION.......................................................................................................... 64
14.1. Physical Description of CNTO 24 76.............................................................................................. 64
14.2. Packaging ...................................................................................................................................... 64
14.3. Labeling .......................................................................................................................................... 65
14.4. Preparation, Handling and Storage ................................................................................................ 65
14.5. Investigational Product and Device Accountability ........................................................................ 65
15. STUDY -SPECIFIC M ATERIA LS....................................................................................................... 65
16. ETHICA L ASPECTS ......................................................................................................................... 66
16.1. Study-Specific Design Considerations ........................................................................................... 66
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
4
Status: Approved , Date: 15 December 201716.2. Regulatory Ethics Compliance ....................................................................................................... 66
16.2.1. Investigator Responsibilities ....................................................................................................... 66
16.2.2. Independent Ethics Committee or Institutional Review Board ................................................... 67
16.2.3. Informed Consent ....................................................................................................................... 68
16.2.4. Privacy of Personal Data ............................................................................................................ 69
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 70
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 70
17.1. Protocol Amendments .................................................................................................................... 70
17.2. Regulatory Documentation ............................................................................................................ 71
17.2.1. Regulatory Approval/Notification ................................................................................................ 71
17.2.2. Required Prestudy Documentation ............................................................................................. 71
17.3. Subject Identification, Enrollment, and Scree ning Logs ................................................................ 72
17.4. Source Documentation ................................................................................................................... 72
17.5. Case Report Form Completion ...................................................................................................... 73
17.6. Data Quality Assurance/Quality Control ........................................................................................ 73
17.7. Record Retention ........................................................................................................................... 74
17.8. Monitoring ...................................................................................................................................... 74
17.9. Study Com pletion/Termin ation ....................................................................................................... 75
17.9.1. Study Com pletion ....................................................................................................................... 75
17.9.2. Study Termination ....................................................................................................................... 75
17.10. On-Site Audits ................................................................................................................................ 75
17.11. Use of Information and Publication ................................................................................................ 76
REFERENCES ............................................................................................................................................ 78
INVESTIGA TOR A GREEME NT................................................................................................................. 80
LIST OF A TTACHMENTS
Attachm ent 1: Anticipated Events ......................................................................................................... 79
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
5
Status: Approved , Date: 15 December 2017LIST OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Schedule of Study Assessments for the Safety Run -in Phase and the Randomized 
Double -masked Treatment Phase from Screening through the Month 12 
Postoperative Visit .................................................................................................................... 25
Table 2 Schedule of Study Assessments During the Long -term Follow -up Phase* .............................. 27
Table 3: Study CNTO2476MDG1002: Number (%) of Subjects with 1 or More Treatment -
emergent Serious Adverse Events by Preferred Term (Subjects Treated in Phases 1 
and 2a Combined) .................................................................................................................... 35
Table 4: Volume of Blood to be Collected From Each Subject ............................................................... 49
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
6
Status: Approved , Date: 15 December 2017PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 1 July 2015
Amendment 1 21 December 2015
Amendment 2 29September 2016
Amendment 3 15December 2017
Amendments below are listed beginning with the most recent amendment.
Amendment 3(15December 2017 )
The overall reason for the amendment: The palucorcel development program is discontinued for strategic 
business reasons. For this reason, this study protocol is amended to eliminate the 2ndSafety Cohort and the 
randomized masked portion of the study; to reduce the study sample size; to reduce the length of total follow -up 
period from 60 months to 36 months; and to eliminate most secondary and exploratory efficacy assessments.
Applicable Section(s) Description of Change(s)
Rationale: To allow  elimination of the 2ndSafety Cohort and randomized masked portion of the study.
Synopsis ,Objectives and 
Hypothesis ;Efficacy 
evaluations /endpoints;
2. Objectives and 
Hypothesis
9.2.2 EndpointsPrim ary objective s and endpoints : “The randomized Double -masked Treatment 
Phase of the study to assess the effects on visual acuity of a single subretinal 
administration of CNTO 2476 at 1 of 2 doses, compared with the control .” was 
removed.
The primary efficacy endpoint “The proportion of subjects in the randomized 
Double -masked Treatment Phase showing improvement from baseline of ≥15 letters 
in best corrected visual acuity ( BCVA )at the 6 -month visit follow ing treatment with 
1 of 2 doses of CNTO 2476 compared to the control arm ” was removed.
Secondary o bjectives and endpoints : Updated the major secondary objectives and 
secondary efficacy endpoint s to re flect elimination of the Double -Masked Treatment 
phase.
Exploratory o bjectives and endpoints : The exploratory objectives and endpoints 
related to the Double -masked Treatment phase were removed.
Hypothesis : Added a statement about termination of the Double- masked Treatment 
phase.
Synopsis ,Overview of 
study design, subject 
population;
3.1Overview  of Study 
Design ;
3.2 Study Design Rationale
4Subject Population;
Synopsis, Safety Run -in 
Phase
Synopsis, Random ized 
Double -masked Treatment 
Phase
3.2 Study Design RationaleThe total subjects to be screened w as decreased from 400 to 100 subjects to limit the 
total number of subjects in the open -label phase to 21 subjects. A sentence “ This 
represents a significant reduction in scope and duration based on a decision to 
discontinue the palucorcel development program .” was added.
The Figure 1 representing the study design with the Double -masked treatment phase 
was removed.
Updated the text to reflect the elimination of the Randomized Double -masked 
treatment phase.
Updated the target number of subjects to be enrolled in the safety run -in phase from 
“approximately 75” to “approximately 21”.
Updated the text to reflect that this planned phase of the study was eliminated.
Updates made to the study design rationale to reflect that changes were made to 
minimize the visit burden on subjects and investigators.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
7
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
5. Treatment Allocation and 
Masking
Synopsis; Long -term 
follow -up phase
3.1 Overview  of Study 
Design
8. Prestudy and 
Concomitant medications
16.1 Study specific design 
considerations
9.1.1.4 Long -term Follow -
up Pha sePatient Reported Outcomes planned for the Dou ble-Masked Treatment phase of the 
study were removed.
Updated the control, masking, and randomization details to reflect that the open -label 
phase of the study do not require control, masking, or randomization.
Procedures for randomization and stratification were removed and all subjects w ere 
planned to receive the same dose of 3.0 x105cells.
Table 4 and Table 5 with ma sking procedures for subjects, site personnel, and team 
members were deleted.
The frequency of Long -term Follow -up Phase was updated from every 6 months for 
4years to every 6 months for 2 years.
The total study duration was update to 3 years from 5 yea rs.
Synopsis ,Dosage and 
administration;
6.2Randomized Double -
masked Treatment PhaseUpdated the dosing details to eliminate dosing information for the Randomized 
Double -masked treatment phase.
The details of sham surgical procedure for the control group w ere removed.
Rationale: Updates w ere made to align the protocol with the decision to eliminate the randomized masked portion 
of the study.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
8
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Synopsis ,Efficacy 
evaluations;
9. Study Evaluations
10.1. Completion
10.2 
Discontinuation/Withdrawal
Synopsis, Secondary 
efficacy measures; 9.2.1.2 
Secondary efficacy 
measures
14.4. Preparation, Handling 
and Storage
Time and Events Schedule 
(Table 2)
Footnotes for Time and 
Events Schedule (Table 1)
Footnotes for Time and 
Events Schedule (Table 2)Open -label Safety Run -in Phase : Updated to remove the 2ndSafety Cohort and 
safety revie w by DSMB before the initiation of Randomized Double -masked 
treatment phase.
Randomized Double -masked treatm ent phase : Text updated to remove this phase.
End of Treatme nt orEarly withdrawal : Updated to reflect that the final visit will 
be conducted on Month 36.
The pharmacogenomic evaluations were eliminated.
The additional assessments of contrast sensitivity, low luminescence BCVA (best 
corrected visual acuity ), healt h related quality of life, and MN read w ere removed.
Exploratory efficacy measures w ere removed.
The use of software prediction tool to predict the treatment of dry AMD was 
eliminated.
The sentence “ To support the masking of the trial, a vapor -phase shippe r containing 
no CNTO 2476 vials will be shipped for subjects a ssigned to the sham surgery arm” 
was removed.
The ‘ DNA bl ood samples for genetic testing’ was removed.
The columns for Months 42, 48, 54, and 60 (End of Study ) visit were deleted. 
The assessme nts of low luminescence visual acuity, contrast sensitivity, MN read, 
microperimetry, and NEI-VFQ -25, and 3 -item Near Vision Subscale, and SF -36, FRI
were removed.
The phrase “ the Double- masked Treatment Phase” was removed from the Note 2 in 
the footnote.
Bullet ‘g)’ was updated to reflect that the double -blind masked phase w as eliminated 
from the study
The follow -up phase was updated to 2 years
The abbreviations and expanded forms of NEI -VFQ -25 and SF -36 were removed.
Synopsis ,Statistical 
methods;
11. Statistical MethodsUpdated to reflect that descriptive statistics will be used instead of previously 
planned formal statistical testing.
The statistical methods planned for primary, secondary, exploratory endpoint 
analyses were removed.
Updates w ere m ade to depict that all the subjects receiving treatment will be 
considered for safety analyses.
11.2 Sample size 
determination
11.5 Pharmacogenomic 
analyses
11.6 Data and Safety 
Monitoring BoardUpdated the text to reflect that 21 subjects w ill be included in the study for an 
adequate clinical assessment of safety and usability of the novel delivery system 
instead of using the BCVA response rates betw een the control group and 
CNTO 2476 group for s ample size determination.
The pharmacogenomic analyses were eliminated.
Updated the text to reflect that no further DSMB meetings will be held and DSMB 
will be disbanded until further decision from Janssen’s to reform the DSMB.
Rationale: The first Safet y Cohort having already been done and the efficacy portion of the study no longer 
planned, there is no need to describe the rationale for the sham surgical procedure.
Synopsis;
3.2 Study Design Rationale
5. Treatment allocation and 
masking
16 Ethical AspectsThe rationale for performing the sham surgical procedure was removed.
Rationale: Minor errors w ere noted .
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
9
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
10
Status: Approved , Date: 15 December 2017Amendment 2 (29Sept 2016 )
The overall reason for the amendment: to include modifications to inclusion and exclusion criteria taken from 
learning acquired through the first 21 subjects ( the initial Safety Cohort ), to include a 2ndSafety Cohort of 
21additional subjects agreed upon by the DSMB , to expand the screening to treatment window  to 45 days and to 
include additional baseli ne assessments (axial length). Other modifications are in included to provide clarity to 
study sites where there w as am biguity, or the protocol w as silent on logis tical iss ues that have arisen. Editorial 
changes were made to improve the overall clarity of the Protocol.
Applicable Section(s) Description of Change(s)
Overvie w of Study 
Design
Screening Phase
Safety Run -in Phase
Subject Population
Inclusion Criteria
Exclusion CriteriaUpdated the target number of subjects to be enrolled in the study to “approximately 
285subjects ”.Specified the screening period of upto 45 days before initial randomization 
that subjects must be confirmed w ith a diagnosis of GA of the macular secondary to age -
related macular degeneration with associated vision loss . Clarified vision between the 
patient’s eyes as “not clinically equal” or “ clinically equal” for the relevant disease state 
of the eyes . Updated the approximate number of subjects to 75 in the Safety Run -in Phase 
of the study. Specified the addition of the 2ndSafety Cohort. Also updated the number of 
sites for this phase of the study to 20.
Clarified that subjects mayhave the option to donate their eyes for histological evaluation 
post mortem. Specified the screening period of up to 45 days betw een a subject giving 
written informed consent and occurrence of treatment . Also clarified that screening 
activities need not take place in one visit. Clarifie d that the BCVA examination to 
determine eligibility should be performed prior to any other ocular study procedures that 
might interfere with vision assessments (dilation, bright light examination, etc ). Also 
specified that a xial length will be recorded at baseline. Indocyanin green angiography will 
be performed for all subjects unless discussed with the Sponsor
Clarified that a minimum of the first 3 eligible subjects at each center will receive active 
treatment in an uncontrolled, open-label Safety Run -in Phase .Clarified that the first 
21subjects at 8 (not 7) study sites will comprise the initial Safety Cohort , and specified the 
addition of the 2ndSafety Cohort
Updated protocol to specify that approximately 400 subjects will be screened to provide
approximately 285subjects enrolled .The change reflects the additional safety run -in 
subjects resulting from an increase in the number of sites , the 2ndSafety Cohort and an 
estimated increase in the percentage of screen failures . Also updated the protocol to 
specify that s creening fo r eligible subjects w ill be performed w ithin 45days before 
administration of the treatment .
Criterion 2 (renumbered to 2.2) was updated to indicate AMD confirmed within 45 days 
prior to initial randomization. Diagnosis to be verified by the central readi ng center .
Macular Photocoagulation Study (MPS) disc areas (DA) of 0.5for all subjects . In the 
Safety Run -in Phase only there is no maximum DAas long as the criteria for photography 
can be met and the surgeon determines that the GA size will not impede cell delivery. 
Criterion 3 (renumbered to 3 .2)was updated to indicate that t he treatment eye will be 
that with the w orse BCVA at screening. IfBCVA is clinically equivalent, the eye with the 
larger GA determines the study eye.
Criterion 1(renumbered to 1.2)was updated to state “subjects with a history of 
neovacular (“wet”) AMD …… or fluid. In cases where imaging is inconclusive, review of 
thecase with the study site, considering history and imaging will determine eligibility ”
Criterion 7 (renumbered to 7.2) was extended to include “Subjects who have received 
anti-VEGF treatment without a confirmed diagnosis of wet AMD or who have participate d 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
11
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Time and Events 
Schedule (Table 1)
Footnotes for Time 
and Events Schedule
Time and Events 
Schedule (Table 2)in previous studies for AMD may be considered eligible if these treatments/study 
participation w ere given at least one year prior to enrollment”
Criterion 8 (renumbered to 8 .2)was updated to “p revious intraocular surgery within 3
months prior to screening in either ey e.Previous treatment with Visudyne®, external -beam 
radiation therapy, or transpupillary thermotherapy in the study eye at any previous time 
point”
“Visual Acuity” was replaced with “Best Corrected Visual Acuity” (BC VA)
Low Luminance Visual Acuity was added as a separate Study Assessment at Screening, 
Week 4, and at Month s 2,3, 6 and 12. Axial Length was added as a Study Assessment at 
Screening. Footnotes for several items on Table 1 w ere re -numbered to accurately reflect 
the new assessments added to the table.
Note 1 w as updated to reflect that screening procedures could occur 45 days prior to 
treatment and over multiple days. Also it states thatBCVA will be performed twice and 
the best value (lowest logMAR value) will be used as the subject ’s baseline BCVA value. 
Footnote (b) w as updated. A new  footnote (c) “Axial length should be recorded once at 
screening as a baseline measure. Any instrument may be used OR measurement taken 
from the subjects me dical records ma y be utilized. Measurement, instrument and date of 
recording w ill be noted in the CRF . Indocyanin green angiography will be performed for 
all subjects unless discussed with the Sponsor ” was added . Added footnote (l) to indicate 
that SD -OCT m ay optionally b e performed at Day 1 post -operatively or Day 2
A separate line to detail “Low Luminance Visual Acuity: was added for Months 18, 24, 
30, 36, 42, 48, 54 and 60 as it had previously been ambiguous when this assessment took 
place.
Section 1.3 The Cell 
Delivery System
Section 3.1 Overview 
of Study DesignThis section was rew ritten to be more general. Reference is made to the Investigational 
Product Manual for detailed Delivery System information.
Updated the target number of subjects to be enrolled in the study to “approximately 
285subjects ”. Specify the screening period of up to 45 days before treatment that subjects 
must be confirmed with a diagnosis of GA of the macular secondary to age -related 
macular degeneration with associated vision loss. Clarified visio n between the patient’s 
eyes as “not clinically equal” or “ clinically equal” for the relevant disease state of the 
eyes. Updated the approximate number of subjects to 75 inthe Safety Run -in Phase of the 
study. Also updated the number of sites for this phase of the study to 20. Also specified 
that a minimum of 7 different surgeons would be required during the safety run -in phase.
Specified the addition of the 2ndSafety Cohort.
Screening Phase : updated the protocol to specify that subjects may be screened over a 
period of 45 days prior to treatment, and that BCVA exa minations would be done prior to 
any other ocular study procedures that w ould interfere with vision assessments such as 
dilation or bright light assessments. Also specified that a t baseline, dilated fundus 
examination readings will be carried out on all su bjects . In addition, axial length will be 
recorded in the CRF. Indocyanin green angiography will be performed on all subjects 
unless discussed with the Sponsor .
Safety Run -in Phase: Updated the protocol to reflect that a minimum of the first 3 eligible 
subjects at each center will receive active treatment in an uncontrolled, open -label Safety 
Run-in Phase to assess the safety of the surgical procedure and Delivery System , and to 
ensure the familiarity of the surgeons with the device and the procedure. Also specified that 
the first 21 subjects at the first approximately 7 sites would comprise the initial Safety 
Cohort. Specified the addition of the 2ndSafety Cohort.
Double -masked Treatment Phase : Included the sham surgical procedure among the 
treatments to be adm inistered at the clinical site on Day 1.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
12
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Section 3.2
Study Design 
Rationale
Section 3.2.2
Section 3.2.6 
Patient -Reported 
Outcomes
Section 4 Subject 
Population
Section 4.1 Inclusion 
Criteria
Section 4.2 Exclusion
Criteria
Table 4
Section 9.1.1 
Overvie w
Section 9.1.1.1 
Screening Phase
Section 9.1.1.2 
Open -Label Safety 
Run-in PhaseFigure 6 Schematic Representation of Study CNTO2476MDG2002 was updated and now  
becomes Figure 1 as the original Figures 1 -5 in Section 3.1 were removed from the 
protocol and are now located in the Investigatio nal Product Manual.
Specified the addition of the 2ndSafety Cohort.
Replaced “suture” with “ conjunctival incision, a scleral mark and a masking stitch ”
Corrected a typographical error, replacing “retinal” with “retinal experts”
Updated the subject population to indicate that “Approximately 400 subjects w ill be 
screened to provide approximately 285subjects enrolled. Screening for eligible subje cts 
will be performed within 45 days before administration of the treatment.
Changes to the Inclusion Cri teria are described in the Summary of Changes in the 
Synopsis (see Page 6).
Changes to the Inclusion Criteria are described in the Summary of Changes in the 
Synopsis (see Page 7) .
A correction was made in footnote “a” to indicate that potential to become unmasked upon 
ophthalmic examination and/or review  of AEs, SAEs and ocular procedure results
The follow ing was added to the protocol “ New technology assessments ,eg,Optical 
Coherence Tomography Angiography (OCT -A) and intraoperative Optical Coherence 
Tomography , may be performed at the surgeon or investigator’s discretion but do not 
substitute for any of the mandatory evaluations listed in this protocol ”
Text w as added to specify that a subject failing screening for a reason determined to be 
temporary c ould be re -screened per the follow ing criteria:
 Elevated IOP, uncontrolled blood pressure, elevated liver enzymes , decreased 
platelets and decreased renal function, if correctable w ith treatment or time
 Acute infections, after successful treatment
 Time-bound restrictions (eg, Exclusions 8, 9, 12, 20, 21 and 25) after an appropriate 
waiting period such that the exclusion no longer applies
 Use of prohibited prior medications, after an appropriate w aiting period.
In addition, Potential patients who fai l screening for visual acuity, retinal anatomy or other 
ocular find ings should not be rescreened. Any rescreening request not mentioned here 
should be discussed with the study Medical Monitor. For rescreened subjects, imaging 
studies do not have to be repe ated if performed in the 60 days prior to start of new 
screening. For rescreened subjects, clinical laboratory exams (bloodw ork) do not have to 
be repeated if performed in the 45days prior to start of the new  screening . Furthermore, 
Axial length will be r ecorded at baseline. Indocyanin green angiography will be performed 
for all subjects unless discussed w ith the Sponsor . Changes in concomitant medications 
will be recorded on Day 1
Clarified that the study will begin with a minimum of 7 surgeons performing
approximately 3 open -label procedures to complete an initial Safety Cohort of 21 subjects. 
A minimum of 7 surgeons were chosen for the Safety Cohort based on the amount of 
device users needed to identify complications with a surgical procedure and device .Added 
“significant loss of vision defined as loss of ≥15 letters compared to baseline in the first 
month post -surgery,” as an event of special interest. Specified the addition of the 2ndSafety 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
13
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Section 9.1.1.3 
Randomized Double -
Masked Treatment 
Phase
Section 9.2.1.2 
Secondary Measures
Section 9.2.2 
Endpoints
Section 9.3.3 
Immunogenicity 
Assessments
Section 9.7.1 Adverse 
Events
Section 9.7.2 Clinical 
Laboratory Tests
Section 11 Statistical 
Methods
Section 11.7 Data 
Safety Monitoring 
Board
Section 12.1.1 
Adverse Event 
Definitions and 
Classifications
Section 14.2 
Packaging
Section 14.4 
Preparation, Handling 
and Storage
Section 14.5 
Investigational Cohort.
Clarified that a sham surgical procedure w ill take p lace on Day 1 (pre -operative visit on 
the treatment day). 
Included “visual assessment” among assessments to be performed. 
Major Secondary Endpoints: specified that “RS plateau ” was being measured
Clarified that Blood samples will only be collected during study assessments for the safety 
run-in phase and the randomized double -masked treatment phase from screening through 
the Month 12 postoperative visit
Updated the text of the protocol to indicate that a dverse events will be reported by the 
investigator or the subject (or, when appropriate, by a caregiver, surrogate, or the subject's 
legally acceptable representative) for the duration of the study
Aligned the text of the penultimate paragraph with the Inclusion Criteria, ie, “ Female 
subjects must be post -menopausal with last menses 12 months prior, or longer, OR a 
measure d follicle stimulating hormone ≥26 m IU/mL ”
Updated the text of the protocol to state that data from approximately 75subjects 
participating in the open -label safety run -in, after have completed 1 month of follow -up, 
will be analyzed for simple descriptive statistics for key safety and efficacy measures .Also 
specified the analysis of data after the 21 subjects of the 2ndSafety Cohort have completed 
1 month of follow -up.
Specified the addition of the 2ndSafety Cohort.
Under Adverse Event Associated With the Use of the Drug, the following was added to the 
text of the protocol “ The surgical procedure and delivery of CNTO 2476 result in a small 
retinal detach ment per procedu re guidelines. This in itself should not be listed as an 
adverse event ”. 
It was clarified in the protocol that each vial of product is for single us. In addition, the 
following text was added “ Each vial is enclosed in a paperboard carton with appropriate
labeling on the carton ”.
The text in the protocol w as updated to exclude temperature deviations that were 
applicable to manufacturing only . In addition, the following was added to the protocol 
“CNTO 2476 is shipped to the clinical site in a liquid nitrog en vapor -phase shipper that is 
also used for short -term storage up to 7 calendar d ays after shipment. The distribution is on 
a just -in-time basis fo r each treatment in the trial. The shipment for a subject w ill be 
triggered when enrolled or randomized thro ugh the IWRS . To support the masking of the 
trial, a vapor -phase shipper containing no CNTO 2476 vials will be shipped for subjects 
assigned to the sham surgery arm ”
The text in the protocol w as updated to the follow ing “ The investigator is responsible fo r 
ensuring that all CNTO 2476, Delivery System devices received at the site are inventoried 
and accounted for throughout the study, per the requirements in the Investigational Product 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
14
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Product and Device 
Accountability
Section 16.1 Study -
Specific Design 
Considerations
Section 17.8 
MonitoringManual. All CNTO 2476 w ill be stored and disposed of according to the sponsor's 
instructions, per the Investigational Product Manual. Study -site personnel must not 
combine contents of the CNTO 2476 containers ”
Clarified there are 2 Safety Cohorts.
The follow ing text was added to the protocol “ Representatives from the sponsor company, 
Janssen and/or its’ designees may be present at the clinical facility, in the operating room 
during surgery or observing remotely. This is to ensure oversight of aspects of the surgical 
procedure and protocol ”
Throughout the 
Protocol“Maximum Reading Speed, MRS” has been replaced w ith “Reading Speed, RS”
“Discontinue from the study”, “ Drop out of the study” replace dwith “Withdrawal ….” 
Withdrawa l from the study”
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
15
Status: Approved , Date: 15 December 2017Amendment 1 (21Dec 2015 )
The overall reason for the amendment: Include the Functional Reading Index (FRI) as a major secondary 
objective, update the Time and Events Schedule to reflect tests no longer to be done, update some Exclusion 
Criteria, correct the stratification data and clarify how informed consent i s to be obtained. Editorial changes were
made to improve the overall clarity of the Protocol. 
Applicable Section(s) Description of Change(s)
Synopsis ,Objectives
and Hypotheses ;
Synopsis ,Overview 
of Study Design
Synopsis ,Subject 
Population
Synopsis Exclusion 
Criteria
Synopsis ,Secondary 
Efficacy Endpoints
Synopsis ,Statistical 
Methods
Time and Events 
Schedule
Introduction
Section 1.1.1.1 
Mechanism of Action
Section 1.1.1.2
Section 2.1 
Objectives
Section 3.1 Overview 
of Study Design
Section 3.2.4
Section 3.2.6 Patient -
Reported Outcomes
Section 4 Subject Added Functional Reading Index (FRI) to the list of major secondary objectives
Updated target number of subjects to 255. Also update the subjects in the safety run -in 
phase to 45, and the number of sites to 15.
Described the screening process including BCVA examinations performed to determine 
patient eligibility
Updated the total number of subjects to be screened, and also update the numbe r of 
subjects to be enrolled (open -label safety phase and subjects randomized in 1:1:1 ratio)
Modified Criteria 7.1 and 20.1 (Details in Section 4.2 Exclusion Criteria, below )
Added FRI as a secondary efficacy endpoint
Updated the baseline BCVA strati fication criteria
Removed Visual Acuity Tests on Day 2, and on Days 7 & 15
NEI-VFQ -25, SF -36, Near Vision Subscale (3 -item) and FRI w ill no longer be done on 
Treatment Day 1 (pre -op)
Clarified that an additional optional pre -screening visit may be perfor med to determine 
potential subject BCVA for eligibility purposes this was already noted in the original 
protocol
Clarified that Pharmacodynamic Marker Testing will not be done. Clarified that no 
samples will be collected for immunogenicity testing after th e Month 12 visit
Removed referenc e to blood sample volume after Month 12 ( no samples will be collected )
Editorial changes to capture additional files names previously listed as “data on file”
Re-wrote for clarity
Re-wrote for clarity
Added the Functional Reading Index as a Secondary Objective
Updated the number of subjects in run -in phase and the number of sites. Updated Figure 6 
to capture the number of subjects and sites
Specified how stratification would be done
Re-wrote the description of the NEI- VFQ -25 for clarity
Updated the section with a description of the Functional Reading Index
Updated the number of subjects enrolled into the study, including those from the 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
16
Status: Approved , Date: 15 December 2017Applicable Section(s) Description of Change(s)
Population
Section 4.2 Exclusion 
Criteriaopen -label safety run -in phase
Bullet point 7 w as renumbered 7.1, and “AMD ”changed to “AMD (dry or w et)”
Bullet point 20 w as renumbered to 20.1 and the text “… has participated in other 
ophthalmic investigational drug studies within 6 months of Day 1, or is currently enrolled 
in an investigational study” deleted
Section 5. Treatment 
Allocation and 
Masking
Section 8 Prestudy 
and Concomitant 
Therapy
Section 9.1.1 
Overvie w
Section 9.2.2
Section 11. Statistical 
Methods
Section 11.3.2 Major 
Secondary Endpoint 
Analyses
Section 16.2.3. 
Informed ConsentDefinition of BCVA was added
Text describing the stratification used was clarified and corrected to the below :
0.6 log MAR (20/80) to 1.3 logMAR (20/400) inclusive (i.e. the moderate loss 
stratum)
1.32 logMAR (20/400-1 letter) to 1.6 logMAR (20/800) inclusi ve, ie, the low vision 
stratum
The use of peri -operative and post -operative medications was clarified
Table 6 w as simplified and updated with corrected volumes of blood to be collected from 
each subject during the course of the study
Text w as introduced to describe how  patient eligibility would be determined based on the 
results of BCVA examinations done at the screening visit
The Functional Reading Index w as added as a major secondary endpoint
The major secondary endpoint of LL BCVA was re -written as the following to provide 
clarification and additional detail
Mean change from baseline at 6 and 12 months in low  luminance BCVA (LL 
BCVA) letters following treatment with CNTO 2476 compared to the control arm.
Proportion of subjects w ith gain of >=15 letters from baseline at 6 and 12 months in 
LL BCVA following treatment with CNTO 2476 compared to the control arm.
BCVA was defined and the stratification re- written as below:
0.6 log MAR (20/80) to 1.3 logMAR (20/400) inclusive (i.e. the moderate loss 
stratum), and 
32 logMAR (20/400-1 letter) to 1.6 logMAR (20/800) inclusive (i.e the low  vision 
stratum)
A description was provided for how  data analysis would be performed after the first 
21subjects , and after all subjects participating in the open -label safety run -in phase had 
completed 1 month of follow -up.
Text w as clarified to include subjects gaining 15 LLBCVA letters. The sensitivity 
analyses were also clarified to include LLBCVA letters
Clarified that all study sites will be asked by the Sponsor to obtain informed consent using 
a validated electronic system instead of a paper -based process. An additional description of 
the process of obtaining informed consent is provided
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
17
Status: Approved , Date: 15 December 2017SYNOPSIS
A Phase 2b, Multicenter, Double -masked, Randomized Study Evaluating the Safety and Clinical 
Response of Subretinal Administration of CNTO 2476 in Subjects with Visual Acuity Impairment 
Associated with Geographic Atrophy Secondary to Age Related Macular Degeneration
CNTO 2476 is an allogeneic somatic cell therapy medicinal product derived from the isolation and 
ex-vivo expansion of human umbilical tissue-derived cells (hUTC) that is to be injected in the subretinal 
space of the eye of subjects with retinal degeneration. In addition to impact ingretinal pigment epithelium 
(RPE)cells, CNTO 2476 appears to preserve photoreceptors, and inner retinal cells.
Study CNTO2476MDG2002 is a Phase 2b study to evaluate the safety and usability profile of the 
procedure and the Delivery System , as well as to assess the clinical efficacy, safety, and tolerability of a 
single subretinal administration of CNTO 2476 at 1 of 2 doses , compared with the control.
OBJECTIVES AND HYPOTHESIS
Primary Objective s
The primary objective of the open -label Safety Run-inPhase is to evaluate the safety and performance
profile of the suprachoroidal surgical approach and the Delivery System . 
Major Secondary Objectives
The major secondary objectives of this study are the following: 
 to assess the safety and performance profile of the Delivery System , the safety and tolerability of the 
suprachoroidal surgical approach, and the safety and tolerability ofCNTO 2476 cells in the open -
label Safety Run -in Phase
 to assess the effects of CNTO 2476 on anatomic correlates of treatment, including change in the area 
of geographic atrophy (GA)
 to assess the effects of CNTO 2476 on additional and alternative efficacy outcomes including 
duration of clinical response .
Hypothesis
The primary hypothesis of the open label safety phase of this study is that the novel subretinal delivery 
system is sufficiently safe and usable to deliver cells to the subretinal space. An additional hypothesis is 
that palucorcel is safe and well tolerated when delivered as a single d ose to the subretinal space. 
OVERVIEW OF STUDY DESIGN
This is a multicenter Phase 2b study. A target of approximately 21subjects will be enrolled in this study.
This protocol amendment represents a significant reduction in scope and duration of the study based on a 
decision to discontinue the palucorcel development program.
The target population will be subjects at least 55 y ears of age and no older than 90years ,inclusive with a 
confirmed diagnosis of GA of the macula secondary to age-related macular degeneration, with associated 
vision loss, confirmed within 45days prior to initial randomization by the central reading center using 
fundus and/or autofluorescence , fluorescein angiography , and fundus photography . In subjects with
neovascular AMD in 1eye, the eye with GA must be the worse eye. In subjects with bilateral GA and the 
vision between both eyes not clinically equal, the eye with the worse vision will be treated in order to 
minimize risk to the subject’s vision. In cases where the BCVA of the 2 eyes is clinically equal, the eye 
with more extensive GA as demonstrated on the imaging studies will become the study eye.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
18
Status: Approved , Date: 15 December 2017The Safety Run-in Phase consists of approximately 21subjects (the first 3 subjects at each of 
approximately 8 sites) who will first be enrolled in an open-label assessment of the safety profile of the 
procedure and the Delivery System. During the Safety Run-in Phase, subjects will receive a CNTO 2476 
dose of3.0 x 105cells in 50µL.The first 21subjects in the Safety Run- in Phase will be theinitial Safety 
Cohort . 
The safety profile of the procedure and the Delivery System will be assessed after the first 21subjects
(the initial Safety Cohort) have been treated and followed for a minimum period of 1month. An external 
Data and Safety Monitoring Board (DSMB) will be commissioned for this study. 
The Randomized Double -masked Treatment Phase of the study was planned to follow the DSMB’s 
evaluation of the safety phase data and its supportive recommendation to advanc e to the randomized 
Double- masked Treatment P hase. This cohort was to consist of approximately 210 subjects for evaluation 
of both efficacy and safety. However, the Double -masked Treatment Phase has been eliminated from this 
study protocol.
The study will consist of a 12-month acute phase, followed bya 2-year maximum duration follow -up 
period (3 years total) for all subjects . 
Screening Phase
Prior to the full study screening phase , optional BCVA pre -screening may be done to evaluate subject s for 
BCVA eligibility . In this case, subjects must sign an optional pre-screening informed consent form (ICF)
prior to testing. The site will determine results of local testing and indicate if the subject is eligible for full 
study screening. If the BCVA test indicates the subject meets the necessary eligibility criteria, he or she 
will enter the full screening phase after signing the full study ICF for determination of full study 
eligibility.
All subjects will be required to give written informed consent to participate in the trial. 
After giving written informed consent, subjects may be screened over a period of up to 45days prior to 
treatment to assess their eligibility for the study according to the inclusion and exclusion criteria defined 
for this study. The screening process may occur over a period of days and need not take place in one visit . 
Patient eligibility will be determined based on the results of 2 BCVA examinations performed at the 
screening visit. These examinations can occur on the same day or subsequent days. The better of the 2 
logMAR BCVA scores will be used for eligibility and randomization. These examinations should be 
performed prior to any other ocular study procedures that might interfere with vision assessments 
(dilation, bright l ight examination etc) . 
Visual acuity tests, contrast sensitivity, MN Read, i ntraocular pressure (IOP) , slit lamp examinations 
(including lens mobility examination), microperimetry, fundus photography, spectral domain optical 
coherence tomography (SD-OCT), fundus autofluorescence, and fluorescein angiography , will be 
performed forall subjects. Axial lengt h will be recorded at baseline. Indocyanin green angiography will 
be performed for all subjects unless discussed with the Sponsor.
Other assessments will include m edical history, genomic material from consented subjects, demographics, 
a targeted physical examination, vital signs, routine laboratory androutine urinalysis In addition blood 
samples for immunogenicity, medication history, concomitant medications, the NEI-VFQ-25 and Near 
Vision subscale , the SF-36 and FRI will be collected.
Safety Run -in Phase
The first 3 eligible subjects at each center will receive active treatment in an uncontrolled, open-label 
Safety Run-in Phase to assess the safety of the surgical procedure and Delivery System , and to ensure the 
familiarity of the surgeons with the Delive ry System and the procedure . The first 21subjects at the first 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
19
Status: Approved , Date: 15 December 20178study sites will comprise the initial Safety Cohort. Enrollment into the Safety Run- in Phase will be 
staggered across sites to ensure that the outcomes and learnings from earlier procedures can be transferred 
to all participating surgeons who will perform subsequent procedures. A 1-week interval for information 
sharing is appropriate since most procedure- related adverse events ( AEs)are expected to be apparent 
within hours of surgery.
Long -Term Follow -up Phase
Following the 12 -month acute phase of the study, subjects will be followed every 6 months for 2years in 
the Long -term Follow -up Phase. 
SUBJECT POPULATION
Approximately 100 subjects will be screened to provide approximately 21subjects enrolled.
Screening for eligible subjects will be performed within 45days before administration of the treatment.
Inclusion Criteria
Each potential subject must satisfy all of the following criteria to be enrolled in the study. 
1. Subject must be a man or woman at least 55 years to 90years of age, inclusive.
2.2 D iagnosis of GA secondary to AMD confirmed within 45days prior to initial randomization . 
Diagnosis verified by the central reading center using fundus photographs and including the 
following;
 The study eye must have at least 1GA lesion that involves the fovea, and a Macular 
Photocoagulation Study (MPS) disc areas (DA) of 0.5and 7(1MPS disc area equivalent 
to 2.54 mm2onthe retina) determined by screening images of fundus autofluorescence 
photographs as calculated by the reading center. If GA is multifocal, at least one lesion 
must be 0.5 DA.
o In the Safety Run-in Phase only, DA of 0.5is allowed with no maximum
specifi ed area, as long as thecriteria below for photography can be met and the 
surgeon determines that the GA size will not impede cell delivery .
 Geographic atrophy must be able to be photographed in its entirety and may be contiguous 
with peripapillary atrophy . 
 Retinal photographs , fundus autofluorescence images, and angiography of sufficient 
quality, allowing assessment of the macular area according to standard clinical practice, 
can be obtained. 
 The imaging center must be able to delineate and confirm perip apillary atrophy with 
fundus photography and fundus autofluorescence. 
 Images must include the central field 1, 2, and 3 field images as defined by the University 
of Wisconsin standards as well as a supero- temporal image to capture the subretinal 
injectio n area if possible. 
3.2 Study eyes will have a BCVA of 20/80 to 20/800 (Early Treatment Diabetic Retinopathy Study  
[ETDRS ]logof the minimal angle of resolution (logMAR )value 0.6-1.6). The treatment eye 
will be that with the worse BCVA at screening. IfBCVA is clinically equivalent, the eye with 
the larger GA determines the study eye.
4. Subject is a suitable candidate for ophthalmologic surgery, is willing and able to comply with the 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
20
Status: Approved , Date: 15 December 2017surgical procedure, scheduled visits, treatment plan, laboratory tests and other study procedures. 
Subject has met criteria of the surgery center anti- coagulation protocol, if applicable.
5. Female subjects must be post-menopausal with last menses 12 months prior, or longer, ORa 
measured follicle stimulating hormone 26mIU/mL.
6. Male subjects must be sterile or willing to use 2approved methods of contraception from first 
day post-operatively to 3 months post-operatively (approved methods of contraception include 
condom with spermicide, a sterile sexual partner, a sexual partner using oral or implantable 
contraceptive or an intrauterine device with spermicide, a diaphragm with spermicide, or 
cervical cap with spermicide).
7. Each subject must sign an ICF indicating that he or she understands the purpose of and 
procedures required for the study and are willing to participate in the study. 
Exclusion Criteria
Any potential subject who meets any of the following criteria will be excluded from participating in the 
study
1.2 Subject has a history of neovascular (“wet”) AMD in the treatment eye, including evidence of 
retinal pigment epithelium rips or evidence of subretinal or choroidal neovascularization or 
fluid .In cases where imaging is inconclusive, review of the case with the study site, considering  
history and imaging will determine eligibility. History or evidence of neovascular AMD in the 
fellow eye is allowed, if anti-vascular endothelial growth factor (VEGF) therapy has not been 
required for at least 8 weeks prior to screening.
2. Geographic atrophy se condary to any causes other than AMD in either eye
3. A diagnosis of glaucoma with an IOP 25 mmHg while being treated with an ocular 
hypotensive drug. Treatment should be no more than 1drug preparation/combination, which can 
contain 1or 2ocular hypote nsive active ingredients ; subjects receiving more than 2ocular 
hypotensive active ingredients are excluded. Note : subjects with a diagnosis of ocular 
hypertension (not glaucoma) are eligible to participate whether or not they are being medically 
treated.
4. Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above Grade 2 per 
Age-Related Eye Disease Study (AREDS) scale or any other ophthalmologic condition that 
reduces the clarity of the media that, in the opinion of the investiga tor or reading center,
interferes with ophthalmologic examination (eg, corneal abnormalities, inadequate pupillary 
dilation), surgery or imaging in the study eye
5. Myopia >-8 diopters and subjects with >4 diopters of astigmatism, and >+10 diopters of 
hyperopia. Note: clinical evidence of retinal degeneration secondary to pathological myopia will 
exclude the subject as will a scleral ectasia with or without high myopia .
6. Evidence of other significant ophthalmologic disease (eg, intraocular inflammatory disease, 
diabetic retinopathy, Stage II, III, or IV macular hole, clinically evident vitreoretinal traction, 
choroidal or retinovascular disease, cystoid macular edema, significant epiretinal membrane, 
significant blepharitis, keratitis, conjunctivitis or staphyloma ) in the study eye
7.2 Previous treatment for confirmed AMD (dry or wet) in the study eye with treatments other than
antioxidant or zinc supplements (eg, AREDS 1 or AREDS2 formula) or other oral vitamin 
supplements .Subjects who have received anti-VEGF treatment without a confirmed diagnosis 
of wet AMD or who have participated in previous studies for AMD may be considered eligible 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
21
Status: Approved , Date: 15 December 2017if these treatments/study participation were given at least one year prior to enrollmen t.
8.2 Previous intraocular surgery within 3months prior to screening in either eye.Previous treatment 
with Visudyne®, external -beam radiation therapy, or transpupillary thermotherapy in the study 
eyeat any previous time point.
9. Previous laser photocoagulation in the study eye (peripheral laser for treatment of a tear is 
allowed if more than 6 months prior to screening except when, in the opinion of the surgeon, 
this would hamper the suprachoroidal cannulation procedure in the stu dy eye)
10. Previous vitrectomy, retinal detachment repair, submacular surgery, other surgical interventions 
targeting AMD, scleral buckling or glaucoma filtration surgery or any other extraocular or 
orbital procedure in the study eye that, in the opinion of the surgeon, would hamper the 
suprachoroidal cannulation procedure in the study eye
11. History of choroidal or scleral rupture in either study or fellow eyedue to uveitis (previous 
trauma in the study eye or fellow eye in the case of good vision in that eye is not an exclusion 
criterion)
12. Uveitis or other intraocular inflammatory disease within past 3 months
13 Active infections of the anterior segment
14. Keratoconus, penetrating keratoplasty, Descemet's stripping endothelial keratoplasty (DSEK), 
radial keratotomy (RK), laser-assisted in situ keratomileusis (LASIK) in the study eye
15. Monocular subjects
16. Subject has known allergies, hypersensitivity, or intolerance to CNTO 2476 or its excipients 
(refer to Investigator's Brochure)
17. Medically not qualified for monitored anesthesia care intravenous sedation
18. Previous cell therapy other than standard blood and platelet transfusions
19. Subject has taken any disallowed therapies as noted in Section 8, (Prestudy and Concomitant 
Therapy) before the planned first dose of treatment
20.1 Subject has received an investigational drug (including investigational vaccines) within 30 days 
before the planned first dose of treatment 
21. Active malignancy (requiring therapy) or history of malignancy requiring therapy within 2 years 
prior to Day 1(with exception of cases of basal cell and squamous cell carcinoma of the skin )
22. History of human immunodeficiency virus (HIV) disease
23. Significant cognitive impairment that interferes with a subject’s ability to participate with the 
testing regimen
24. History of organ or bone marrow transplants
25. History of alcohol or drug abuse within past 2 years
26. Significant hepatic dysfunction (aspartate aminotransferase [AST] or alanine aminotransferase 
[ALT] >3x upper limit of normal [ULN]) ,or significant renal dysfunction (estimated creatinine 
clearance 30mL/min) ,or on renal dialysis
27. Significant uncorrectable coagulopathy, thrombocytopenia (platelets <100 x103/µL) or other 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
22
Status: Approved , Date: 15 December 2017significant bleeding risk. Note: subjects on an anticoagulan t therapy should be considered at low 
risk for new thromboembolic events, and must agree to stop all anticoagulation therapy prior to 
surgery, as follows:
 Warfarin 5 days
 Aspirin 7 days
 Oral Factor Xa inhibitors 3 days (or longer, depending on renal fun ction)
 Dabagatran  3 days
 Low molecular weight heparin  1 day
 Clopidogrel and ticagrelor 5 days
 Prasugrel 7 days
 Ticlopidine 10 days
28 Uncontrolled systemic hypertension on the day of surgery, defined as a systolic blood pressure
180mm Hg. Note : if the subject’s systolic blood pressure can be controlled later by the 
subject’s medical doctor, eligibility for surgery can be re -assessed.
29. Subject has any condition for which, in the opinion of the investigator, participation would not 
be in the best interest of the subject (eg, compromise the well -being) or that could prevent, limit, 
or confound the protocol -specified assessments
30. Subject is an employee of the investigator or study site, with direct involvement in the proposed 
study or other studi es under the direction of that investigator or study site, as well as family 
members of the employees or the investigator
31. Known allergy to iodinated contrast dyes
DOSAGE AND ADMINISTRATION
During the Safety Run-in Phase, subjects will receiv e a CNTO 2476 dose of3.0x 105cells in 50µL.
CNTO 2476 will be delivered using the custom -designed Delivery System and surgical procedure.
Each subject in each target dose group will receive a single subretinal administration of CNTO 2476. 
EFFICACY EVALUATIONS/ ENDPOINTS
Primary Efficacy Endpoint
The primary efficacy measure will be the BCVA testing performed after refraction and under 
standardized photopic lighting conditions and distance using an ETDRS logMAR chart.
The endpoints of the open -label Safety Run-in P hase are all related to the objective of evaluating the 
safety profile of the procedure, Delivery System , and of the implanted hUTC cells.
Secondary Efficacy Endpoints
Assessments will be performed at the 6 -and 12- month visits to evaluate:
 Proportion of subjects losing 15BCVA letters from baseline at 12 months following treatment with 
CNTO 2476
 Change in mean number of BCVA letters from baseline at the 6-and 12-month visits following 
treatment with CNTO 2476
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
23
Status: Approved , Date: 15 December 2017 Growth rate of GAlesion documented at baseline to 6 and 12 months following treatment with 
CNTO 2476 compared to the control arm. The area of GAis determined based primarily on fundus 
autofluorescence as well as fluorescein angiography and fundus photos
Safety Endpoint
 Treatment -related ocular AEs and SAE sand other safety outcomes including markers of 
immunogenicity, safety of the surgical procedure and performance of the Delivery System
IMMUNOGENICITY EVALUATIONS
Serum antibody levels pre-and post-administration of CNTO 2476 will be assessed. The titer of 
confirmed positive samples will be reported .
SURGICAL EVALUATIONS
Data on the conduct of the procedure, including the success of individual elements of the surgical 
procedure and Delivery System performance will be collect ed and tabulated, as well as any complications 
of the procedure or any product quality defects.
SAFETY EVALUATIONS
Any clinically relevant changes occurring during the study must be recorded on the Adverse Event 
section of the CRF . Any clinically signific ant abnormalities persisting at the end of the study/early 
withdrawal will be followed by the investigator until resolution or until a clinically stable endpoint is 
reached. I n addition to AEs, clinical laboratory test sfor hematology, serum chemistry, and urinalysis will 
be performed and reported. In addition, vital signs and physical examination will be measured and 
reported. 
STATISTICAL METHODS
 All outcome assessments will be tabulated using descriptive statistics; no formal statistical testing is 
plann ed for outcome in the Safety Cohort .
Sample Size Determination
The sample size of 21 subjects is based on the number of subjects require dfor an adequate clinical 
assessment of the safety and usability of the novel delivery system . 
Efficacy Analyses
The BCVA respons e is defined as an increase of 15 letters or more from baseline inETDRS letters, a 
magnitude of change that is determined to be clinically important . 
The BCVA, LL BCVA, LLD, contrast sensitivity and growth rate of GA lesion will be summarized with 
descriptive statistics as specified in the SAP.
Other Analyses
Safety analyses will be performed and reported for AEs, the Delivery System and surgical procedure, 
clinical laboratory tests, immunogenicity, vital signs, and physical examination.
Specifically, the number and percentage of subjects who experienced at least 1treatment -emergent 
serious ocular AEwillbe presented in summary tables by treatment group and preferred term according  
to terminology from the Medical Dictionary for Regulator y Activities (MedDRA )as well as by affected 
eyes (events occurring in the treated eye only, in the fellow eye only, and in both eyes). 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
24
Status: Approved , Date: 15 December 2017Ocular TEAEs will be summarized by treatment group and preferred term according to MedDRA 
terminology, as well as by affected eyes (events occurring in the treated eye only, in the fellow eye only, 
and in both eyes). 
The number and percentage of subjects who experienced at least 1treatment -emergent serious AE(SAE)
will be presented in summary tables by treatment group and preferred term, as well as by preferred term 
within system -organ class according to MedDRA terminology. 
The number and percentage of subjects who experienced at least 1treatment -emergent AEwill be 
presented in summary tables by treatment group and preferred term, as well as by preferred term within 
system- organ class according to MedDRA terminology .
Data regarding the Delivery System and surgical procedure will be tabulated by treatment group . A listing 
of all data pertaining to the Delivery System and surgical procedure, as well as any surgical deviations 
and surgical medications, will be provided . Adverse events for subjects who receive surgery but not 
CNTO 2476 cells will be listed . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
25
Status: Approved , Date: 15 December 2017TIME A ND EVENTS SCHE DULE S
Table 1: Schedule of Study Assessments for the Safety Run -in Phase and the Randomized Double -masked Treatment Phase from  Screening through the 
Month 12 Postoperative Visit
Optional Pre -
ScreeningScreen
(seenote)Treat ment Day
1 (pre -op) Day 2Days 7 & 15
(±3d)Week 4
(±3d)Month 2
(±3d)Month 3
(±3d)Month 6
(±3d)Month 12
(±7d)
Visit num ber 1 2 3 4,5 6 7 8 9 10
Informed con sent xax
Inclus ion/Ex clusion criteria x
Medic al Histo ry and demographics x
Vital signs x x x x x x x x x
Phys ical exam x x
Best Corrected Visual Acuity(BCVA) x xbx x x x x
Low Lu minance Visual Acuity x x x x x x
Axial Length xc
Contrast sensitivity x x x x
MN Read x x x x
IOP x x x x x x x x
Slit lamp b iomicroscopy/opht halmos copy x x x x x x x x
Microperimetry assessments x x x x
Fundus phot ography x x x x x x x
SD-OCTlx x x x x x x
Fundu s autofl uorescence x x x x x x x
Fluorescein angiography x x x
Indocyanin green angiography x
Rout ine la boratorydx x x
Rout ine urinalysis x x x
Blood samp lesforimmun ogenicityfx x x x x x x
Medication History x x
NEI-VFQ-25 , SF-36i, and Near Vision Subscale 
(3-item) , FRIx x x
Randomization (for theDouble -masked Treatment 
Phase only)g
CNTO2476 Administ ration xh
PGIC-S x x
PGIC-Q x x
CGIC x x
Change in con comit ant medication s <--------------------------------------------------- Continuous --------------------------------------------------->
Adve rseevents <---------------------------------------------------------- Continuous ---------------------------------------------------------- >
Blood samp les volu mej16.3 mL 0 0 20 mLk16.3mL 10mL 10mL 10mL 16.3mL
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
26
Status: Approved , Date: 15 December 2017BCVA=Best Corrected Visual Acuity; CGIC=Clinician Global Impression of Change; ETDRS=Early Treatment Diabetic Retinopathy Study; IOP=intraocular pressure; 
MNRead=Minnesota reading test; NEI-VFQ -25= National Eye Institute Visual Functioning Q uestion naire;PGIC-Q=Patient Global Impression of Change –Quality of Life; PGIC -
S=Patient Global Impression of Change – Symptoms; SD-OCT=s pectral domain optical coherence tomograp hy;SF-36= Short Form (36) Health Survey , FRI= Functional Reading Index 
questionnaire
Note 1:Screening procedures must occur within45days prior totreatment andmay o ccur over multiple days.An additional optional pre -screening visit may be performed to determine 
potential subject BCVA for eligibility purposes .Atthenext screening visits, BCVA willbeperformed twiceand the best value (lowest logMAR value) will be used as the 
subjects ’baseline BCVA value . 
Note 2: If a subject withdraws early from the Safety Run -in Phase ,the end -of-study assessments (described in Table 2) should be performed.
a)Subjects will be presented with an optional pre -screening ICF to allow the determination of their BCVA results prior to full study screening. The subjects who meet th eBCVA
eligibility criteria will be further screened to determine the full study eligibility. For the full study eligibility assessm ents, the subject will be presented a separate ICF within 45days
prior to treatment . The pre -screening visit is optional
b)Best Corrected Visual Acuity testing includes BCVA using the ET DRS chart under high illumination and standardized conditions at 4 meters and 1 meter (as needed). .
c)Axial length should be recorded once at screening as a baseline measure. Any instrument may be used OR measurement taken from the subjects me dical records may be utilized. 
Measurement, instrument and date of recording will be noted in the CRF.
d)Includes routine hematology ( hemoglobin, hematocrit, red blood cell count, white blood cell count with differential, platelet count, prothrombin time, and partial thromboplastin time) 
and serum chemistry ( sodium, potassium, chloride, blood urea nitrogen, cre atinine, glucose, aspartate aminotransferase, alanine aminotransferase, gamma -glutamyltransferase, total 
bilirubin, alkaline phosphatase, lactic acid dehydrogenase, uric acid , calcium, albumin, and total protein) and urinalysis (dipstick).
e) Optional blood draw (ie, for subjects who provide consent for this blood draw)
f)Includes samples for antibody assay testing.
g) Enrollment and randomization of subjects in the Double-masked Treatment Phase was to follow the DSMB’s evaluation of the Safety Run -in Phase and its supportive reco mmendation 
to advance the study to the Double- masked Treatment Phase. However, the Double -masked Treatment Phase has been eliminated from this study protocol.
h)Includes assessment of Delivery System .
i)SF-36 is included to assess the measurement properties of the NEI -VFQ -25and Near Vision subscale .
j)Blood sample estimates based upon the following volumes per sample: Screening=16.3 mL, DNA=8.5 mL, Day 7=10 mL, Day 15=10 mL, Week 4=16.3 mL, Month 2=10 mL, 
Month 3=10 mL, Month 6=10 mL, Month 12=16 .3mLTotal volume of blood through Month 12 = approximately 107.4 mL.
k)Includes 10mL samples each for Day 7 and Day 15
l)Optional SD -OCT at day 1 (post- operatively) and day 2 may be performed
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
27
Status: Approved , Date: 15 December 2017Table 2 Schedule of Study Assessments During the Long -term Follow -up Phase*
Time Post-treatment
Month 18 (±2wk) Month 24 (±2wk) Month 30 (±2wk) Month 36 (±2wk)
Visit num ber 11 12 13 14
Best Corrected Visu al Ac uity testing x x x x
IOP x x x x
Slit lamp b iomicrosco py / ophthal moscopy x x x x
SD-OCT x x x x
Fundus photography x x x x
Fundu s autofl uorescence x x x x
Concomit ant medication s <------------------------------------------------ Continuous ----------------------------------------------- >
Adverse eventsb<------------------------------------------------ Continuous ----------------------------------------------- >
Footnotes
*After the 12 -month acute phase of the study subjects will be followed for 2 years. Subjects will come in for a follow -up visit every 6 months.
AE=adverse event; I OP=intrao cularpressure; SAE=serious adverse event; SD-OCT=spectral -domain optical coherence tomography .
a)If a subject is withdrawn from the study, he/she will be asked to have the End -Of-Study Visit assessments performed .
b)Only SAEs, ophthalmologic AEs, ongoing AEs from acute phase or any AEs designated as related to treatment or surgical procedu re are recorded.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
28
Status: Approved , Date: 15 December 2017ABBREVIA TIONS
ABCA4 ATP-binding cassettes A4
AE adverse event
AMD age-related macular degeneration
AMD -GA age-related macular degeneration with geographic atrophy
AREDS Age R elated Eye Disease Study 
ALT alanine aminotransferase
AST aspartate aminotransferase 
BCVA best corrected visual acuity 
BSS balance dsalt solution
CFR Code of Federal Regulations
CGIC Clinician Global Impression of Change
CPS critical print size
CRO Contract Research Organization
DA disc area
DARC Digital Angiography Reading Center
DSMB Data and Safety Monitoring Board
eCRF electronic case report form
eDC electronic data capture
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
FRI Functional Reading Index questionnaire
GA geographic atrophy
GCP Good Clinical Practice
GTP Good Tissue Practice
HIV human immunodeficiency virus
hUTC human umbilical tissue -derived cells
ICF informed consent form
ICH International Conference on Harmonisation
IEC Independent Ethics Committee
IOP intraocular pressure 
IRB Institutional Review Board
ITT intent -to-treat
IWRS interactive web response system
LASIK laser- assist ed in situ keratomileusis
LL BCVA low luminance best corrected visual acuity 
LLD low luminance difference
logMAR log of the minimum angle of resolution
MAIA 2 Macular Integrity Assessment 
MCID minimal clinical important difference
MDS microcatheter delivery system 
MedDRA Medical Dictionary for Regulatory Activities
mITT modified intent -to-treat 
MN Read Minnesota reading test
MertK Mer tyrosine kinase 
MPS Macular Photocoagulation Study
NEI-VFQ -25 National Eye Institute Visual Function Questionnaire
NOAEL no-observed -adverse -effect level
PGIC -Q Patient Clinician Global Im pression of Change –Quality of Life
PGIC -S Patient Clinician Global Impression of Change –Symptoms
PQC Product Quality Complaint
PRO patient -reported outcome(s)
pUTC pig umbilical tissue -derived cells
RA reading acuity
RCS Royal College of Surgeons
RGC retinal ganglion cell
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
29
Status: Approved , Date: 15 December 2017RK Radial keratotomy 
ROS rod outer segments 
RPE retinal pigment epithelium
RS reading speed
SAE serious adverse event
SAP statistical analysis plan
SD-OCT spectral domain optic al coherence tomography 
SF-36 Short Form (36) Health Survey
TEAE treatment -emergent adverse event
ULN upper limit of normal
US United States
VEGF vascular endothelial growth factor
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
30
Status: Approved , Date: 15 December 20171. INTRODUCTION
CNTO 2476, BB-IND 13198 ,is an allogeneic somatic cell therap y medicinal product derived 
from the isolation and ex vivo expansion of human umbilical tissue -derived cells (hUTC) that is 
to be injected in the subretinal space of the ey es of subjects with retinal degeneration. In additi on 
to impact ing retinal pigment epithelium (RPE)cells, CNTO 2476 appears to preserve 
photoreceptors, and inner retinal cells. Asa result , treatment with CNTO 2476 may have a 
positive impact on visual function . The putative mechanisms of action of CNTO 2476 relevant to 
age-related macular degeneration (AMD )arestimulating RPE phagocytosis of rod outer 
segments , promoting RPE survival and promoting sy naptogenesis and neuron survival .
Age-related macular degeneration with geographic atroph y (AMD- GA) is a retinal degenerative
disease involving the macula. The pathogenesis of AMD, though not conclusively  defined, 
involves the loss ofphotoreceptors and RPE cells. This loss is thought to be induced by toxic 
agents such as lipofuscin in RPE. The accumulation and deposition of lipofuscin and the 
formation of drusen has been associated with dysfunction and subsequent loss of RPE, resulting 
in degeneration of the overly ing photoreceptors1,6,9,4,13, and sy naptic loss and mislocalization.8,15
Biological functions of RPE cells include phagoc ytosis of rod outer segments (ROS) and 
recycling of visual cycle products. Genetic mutations that affect the normal phagocy tosis and 
visual cycle functions of the RPE cells result in significant deficiencies, underscoring their 
importance maintaining retinal homeostasis.12In particular, mutations in RPE Mer tyrosine 
kinase (MertK) and ATP -binding cassettes A4 (ABCA4) induce AMD -like retinal degeneration. 
The MertK mutation interferes with Mer receptor mediated phagocy tosis in RPE cells and causes 
retinitis pigmentos a, another degenerative disease of the retina in human .5Mutation of lipid 
visual cycle transporter —ABCA4 in the eye increases a toxic byproduct of the visual cycle, 
A2E, a component in lipofuscin, and results in early onset macular degeneration in children.1
Both of these mutations lead to the loss or dysfunction of RPE cells and consequentl y in the 
accumulation of lipofuscin, the formation of drusen, and loss of overl ying photoreceptors.9,11,6
Therefore, overcoming RPE deficiencies could have a significant impact on photoreceptor 
function.
Animal models of AMD -GA presenting all clinical and histological signs of the human disease 
are lacking. Nevertheless, several key elements of AMD -GA pathogenesis can be identified in 
the Royal College of Surgeons (RCS) rat model ,such as phagocy tosis and visual cycle lipid 
metabolism. The RCS rat carries the MertK mutation resulting in diminished phagocy tosis of 
ROS and leading to photoreceptor cell death .14The RPE cells from dystrophic RCS rats showed 
reduced phagocy tosis in vitro. Furthermore, deterioration of the visual cycle associated with 
disease progression was identified by gene profiling in dystrophic RCS rats. The visual cycle 
transporter (ABCA4) was down -regulated with disease progression over time, potentially  lead ing 
to an accumulation of A2E. This is supported by the finding that A2PE, a precursor of A2E, is 
increased in the RCS retina .11Therefore, the RCS rat RPE cells have functional deficits in 
phagocy tosis and visual cycle functions, which are similar to deficiencies that may lead to 
AMD -GA in humans. Finally , RCS rats exhibit early changes in synaptic connectivity  that lead 
to mislocalization and loss of synapses .2
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
31
Status: Approved , Date: 15 December 2017Data from preclinical studies with CNTO 2476 support the hypothesis that CNTO 2476 can 
improve the phagocy tic function of dystrophic RCS RPE cells. In vitro, CNTO 2476 restored 
dystrophic RPE phagocytosis function to the level of normal RPE cells (SCI V-DR14). In vivo, 
subretinal injections of CNTO 2476 into dystrophic RCS rats led to preservation of visual 
function and photor eceptors (SCIV -DR1, SCIV-DR2). Moreover , the presence of CNTO 2476 
resulted in an increase of phagosomes in the RPE and a reduced layer of debris between the 
photoreceptor and RPE (SCO -TD-2009 -0035). This increase in phagocy tosis may lead to a 
reduction of photoreceptor apoptosis. Addition ally,in vitro studies utilizing a purified rat retinal 
ganglion cell (RGC) culture sy stem, further confirmed CNTO 2476 secrete factors that enhanced 
neuronal survival, supported neurite outgrowth and strongly  promoted excitatory  synaptic 
connectivity  (SCO -DR-2015 -0001 ). In addition, CNTO 2476 also promoted survival reduced 
apoptosis of RPE cells exposed to oxidative stress (SCO -DR-2009 -0004 and SCO -DR-2015 -
0002 ). Finally , subretinal injections of CNTO 2476 to the RCS rat also preserved the gene 
expression of ABCA4, a visual cy cle transporter (SCO -DR-2009 -0005).
For the most comprehensive nonclinical and clinical information regarding CNTO 2476 , refer to 
the latest version of the Investigator's Brochure forCNTO 2476.7
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
1.1. Background
1.1.1. Nonclinical Studies
1.1.1.1. Mechanism of A ction
Mechanism of action studies indicated that CNTO 2476 can affect phagocy tic function of 
dystrophic RCS retinal pigment epithelial (RPE) cells, both in vitro and in vivo. Additionally , 
studies performed in human RPE cells demonstrated hUTC promoted survival and reduced 
apoptosis of RPE cell s exposed to oxidative stress. Finall y, in vitro studies utilizing a purified rat 
retinal ganglion cell (RGC) culture system further confirmed CNTO 2476 secrete factors that 
enhanced neuronal survival, supported neurite outgrowth and strongl y promoted excitatory 
synaptic connectivity . Together, these data suggest that CNTO 2476 can potentially  improve 
vision by  enhancing the phagocy tic function of dy sfunctional RPE cells, promoting RPE survival 
and enhancing neuronal survival and function.
1.1.1.2. Pharmacokinetic Profile
The disposition of hUTC were characterized with respect to persistence and systemic 
biodistribution in xenogeneic settings. These studies have indicated that following subretin al 
administration, hUTC persist for approximately  2 to 3 months. In non-target organs in RCS rats 
treated with immunosuppressants, human cell equivalents were detected by polymerase chain 
reaction in the peripheral blood, kidney , liver,and testis up to 14days following subretinal 
administration of hUTC. However, in a study  conducted in nude rats designed to evaluate 
systemic distribution of hUTC to the ovaries, testes, andseminal fluid, no human cells could be 
detected. Taken together, these results indicate that following subretinal administration, 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
32
Status: Approved , Date: 15 December 2017umbilical tissue -derived cells do not engraft and that in contrast to subretinal persistence, 
systemic exposure is limited over time for CNTO 2476 .
1.1.1.3. Immunogenicity
The invivo immunogenicity  of umbilical tissue -derived cells was characterized following 
subretinal administration to pig s. No antibodies to pUTC or cellular immune responses were 
observed in the allogeneic setting following single or repeated subretinal administration of pUTC 
to pigs. In the xenogene ic setting, following single or repeated subretinal administration of 
hUTC to pigs, antibodies to hUTC developed when surgical methods used for cell administration 
caused an intentional or inadvertent retinal perforation. No antibody  responses were observe d 
when targeted subretinal delivery  of hUTC was achieved without retinal perforation. Following 
repeated subretinal delivery , focal mononuclear cell infiltrates and subretinal granulomas were 
observed at the cell administration site. In all animals with subretinal granulomas antibodies to 
hUTC were detected consistent with the premise that they were a manifestion of a xenogeneic 
immune response intended to wall off foreign antigens that were too large to phagocy tose. This 
finding was monitorable by spectral domain optical coherence tomography  (SD-OCT ),which 
revealed resolution into small focal areas of fibrosis over time suggesting the finding was 
reversible. 
1.1.1.4. Toxicology
Thetoxicology  program was conducted in rats and mini- pigs. No tumorigenicity  of CNTO 2476 
was observed in nude rats following subretinal administration at a maximum feasible dose which 
corresponded to approximately  a 5-fold multiple of an efficacious dose in the RCS rat model. No 
systemic toxicity  of CNTO 2476 was observed in rats following a single intravenous dose of up 
to1.5 x 106cells (corresponding to approximately  a 5-fold multiple of an efficacious dose in the 
RCS rat model) when intravenous injection rates were limited to approximately  
1 x 106cells/minute. 
Toxicology  studies con ducted in the Göttingen mini-pigs allowed development and evaluation of 
surgical techniques based on the similar size and anatomy  of the pig eyerelative to human eyes. 
Both CNTO 2476 and pUTC were employ ed to characterize safety  following single and repea ted 
dosing in the xenogeneic and allogeneic setting. No evidence of systemic toxicity  was observed 
in these studies. Vitreoretinal reaction characterized by traction, tractional retinal detachments 
and formation of membranes were identified as the major adverse effects in these pig toxicology 
studies following subretinal administration of cells using the initial surgical procedure . This 
procedure was used in the initial pig toxicology  studies, and clinical Study CNTO2476RPG1001
employ ed full or partial 3-port pars plana vitrectomy , retinotomy , and creation of bleb to provide 
a subretinal space for subretinal injection of cells. A new surgical procedure was subsequently 
developed that use d amicrocatheter to achieve targeted subretinal delivery  of cells that mitigated 
vitreoretinal adverse effects observed in nonclinical studies with the initial surgical procedure. 
Based on these preclinical observation s,the microcatheter delivery  method was implemented in 
clinical Study CNTO2476RPG1002. Following a single subretinal injection of CNTO 2476 in 
pigs the no-observed -adverse- effect level (NOAEL )was considered to be 3 x 105cells and 
1.5 x 106cells using the initial surgical procedure and microcatheter procedure, respectivel y. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
33
Status: Approved , Date: 15 December 2017Following repeated subretinal administration 6 x 104and 1.5 x 106cells were considered the 
NOAELs following repeated subretinal dosing with a microcatheter for CNTO 2476 and pUTC, 
respectivel y based on the observation of subretinal granulomas.
1.1.2. Clinical Studies
Study CNTO2476RPG1001 was a Phase 1 open-label, noncomparative study  to evaluate the 
safet y of a single, unilateral, subretinal administration of CNTO 2476 (using a transvitreal 
approach) insubjects with advanced retinitis pigmentos a.Seven subjects were enrol led inthe 
study and completed 5 -year follow -up. Study  CNTO2476MDG1002 is a Phase 1/2a, multicenter, 
randomized, dose escalation, fellow -eye controlled study  to evaluate the safet y and clinical 
response of a single, subretinal administration of CNTO 2476 in subjects with visual acuity  
impairment associated with geographic atroph y (GA) secondary  to AMD .In September 2014, 
enrollment in this study  was discontinued but long -term follow -up is ongoing. Per the interim 
report, dated 22 January  2015, 35 subjects enrolled in the study ; 33 were evaluable for efficacy  
and safety . Among the 33 subjects, 29 were in the Phase 1 portion of the study  and 4 were in the 
Phase 2a portion of the study .
1.1.2.1. Human Pharmacokinetics
No data on pharmacology , pharmacokinetics, and metabolism of CNTO 2476 in humans are 
available.
1.1.2.2. Efficacy
Although Study  CNTO2476RPG1001 was not designed as an efficacy  study, secondary 
objectives included preliminary  evaluations of changes from baseline in retinal structure and 
visual function. Overall, changes from baseline in visual acuity  and retinal thickness were mixed. 
At the Month 3 visit, 3subjects had measurable increases in retinal thickness in the treated eye, 
3subjects had decreases in retinal thickness, and 1subject had no change from baseline values. 
The data were insufficient to make any meaningful conclusions. No durable chan ges in visual 
acuity were evident anddata were variable . At 12 months post-treatment, no subject had any 
worsening of visual acuity . At the end of the study (Month 6 0), 3 subjects reported lower visual 
acuity (ie, no light perception or a shift from hand motion tolight perception ) at Month 12 .
Study  CNTO2476MDG1002 , as described above, is currentl y ongoing and the efficacy  results 
reflect combined data from both the Phase 1 and 2a portions of the study . At baseline, the 
median best corrected visual acuit y (BCVA )for the 33 treated subjects waslog of the minimum 
angle of resolution ( logMAR ) 1.2 (20/320 )andlogMAR 0.6 (20/80) in the treated ey e and fellow 
eye, respectivel y.At 12 months post-treatment , median BCVA for26subjects was logMAR 1.1 
(20/250) and logMAR0.6 (20/80) inthe treated eye and fellow eye, respectivel y, suggesting an 
improvement in BCVA in the treated eye compared with no change in the fellow eye. The mean 
change from baseline was 5 letters betw een fellow and treated eye at 6months and 6.8 letters at 
12 months. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
34
Status: Approved , Date: 15 December 2017BCVA gains and losses at 6 and 12 months post -treatment were as follows:
Atthe 6-month assessment of BCVA gain, 10 subjects out of 27 (37%)had their treated 
eyes showing a 3-line gain in BCVA. At the same time, 1 subject outof 27 (4 %)had their 
fellow ey es showing a 3-line gain in BCVA. 
Atthe 6-month assessment of BCVA loss, 6 subjects out of 27 (22%) had their treated eyes 
showing a 3-line loss in BCVA. At the same time, 1 subject out of 27 (4%) had the fellow 
eye showi ng a 3-line loss in BCVA.
Atthe 12-month assessment of BCVA gain, 10 subjects out of 26 (39%) had their treated 
eyes showing a 3-line gain in BCVA. At the same time, 1 subject out of 26 (4%) had their 
fellow ey es showing a 3-line gain in BCVA.
Atthe 12 -month assessment of BCVA loss, 6 subjects out of 26 (23%) had their treated ey es 
showing a 3-line loss in BCVA. At the same time, 3 subjects out of 26 (12%) had their 
fellow ey es showing a 3-line loss in BCVA.
Recognizing the study  was designed for safet y, interim efficacy  data suggest that subretinal 
administration of CNTO 2476 may result in BCVA letter gain in some subjects with vision loss 
secondary  to GA. 
1.1.2.3. Safety
Study CNTO2476RPG1001
This was a Phase 1 open-label, noncomparative study  to evaluate the safet y of a single, 
unilateral, subretinal administration of CNTO 2476 in7subjects with advanced retinitis 
pigmentosa . 
Adverse events (AEs) observed during the study were consistent with the postoperative course 
for the surgical procedure. 
There were no adverse clinical observations suggesting an immune response in the treated 
eye. These observations suggest that a single, subretinal injection of CNTO 2476 was not 
immunogenic and did not cause an adverse immune response through 60 months after
treatment. 
Two subjects who received the targeted doses of 3.0 x 105or 5.6 x 105CNTO 2476 cells had 
serious AEs (SAEs )of retinal detachment. In these cases, the mechanism of retinal 
detachment was traction due to proliferation of RPE cells in the vitreous after retinotomy . 
This suggests that transvitreal delivery  of CNTO 2476 is not appropriate . 
Ocular and visual assessments during the 4-year safet y surveillance period remained similar to 
those noted at Month 12.
Study CNTO2476MDG1002
This was aPhase 1/2a study  a to evaluate the safety  and tolerability  of CNTO 2476, administered 
subretinally  using the iScience microcatheter delivery  system (MDS) , in subjects with visual 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
35
Status: Approved , Date: 15 December 2017acuity  impairment associated with GA secondary  to AMD. The study was limited by the inability 
to deliver cells to the subretinal space without a retinal tear.
Thirty -three subjects received CNTO 2476 (29 subjects in the Phase 1 portion of the study  and 
4subjects in the Phase 2a portion of the study ) and were evaluable for safety .Of the 29 subjects 
treated in Phase 1, 28 (96.6%) had at least 1treatment -emergent AE (TEAE). The most common 
TEAEs by preferred term were retinal tear (9 subjects, 31.0%), conjunctival haemorrhage 
(7subjects, 24.1%), and hypertension (7 subjects, 24.1% ). Of the 4 subjects treated in Phase 2a, 
3 (75.0%) had at least 1 TEAE, the most common of which were conjunctival haemorrhage and 
retinal tear (reported for 3 subjects [75.0%] each). Most AEs were considered related to the 
surgical delivery  procedure, or to various co -morbidities. Serious AEs reported for subjects from 
both the Phase 1 and 2a portions of the study  combined are summarized in Table 3. The most 
commonly  reported SAE was retinal detachment (5 of 33 subjects, 15.2%). The incidence of AEs 
and SAEs did not appear to be dose related.
Table 3: Study CNTO2476MDG1002: Number (%) of Subjects with 1 or More Treatm ent-emergent 
Serious Adverse Events by Preferred Term (Subjects Treated in Phases 1 and 2a Combined)
6.0 x 104cells 1.2 x 105cells 3.0 x 105 cells 5.6 x 105cells Total
Subjects Treated 12 3 15 3 33
Subjects with 1 or more 
Treatment- emergent SAEs6 (50.0%) 2 (66.7%) 3 (20.0%) 2 (66.7%) 13 (39.4%)
Preferred Term
Appendicitis 1 (8.3%) 0 0 0 1 (3.0%)
Atrial Flutter 0 0 1 (6.7%) 0 1 (3.0%)
Chronic Obstructive Pulmonary 
Disease1 (8.3%) 0 1 (6.7%) 0 2 (6.1%)
Device Dislocation 0 0 1 (6.7%) 0 1 (3.0%)
Grand Mal Convulsion 1 (8.3%) 0 0 0 1 (3.0%)
Intestinal Obstruction 1 (8.3%) 0 0 0 1 (3.0%)
Metastatic Squamous Cell 
Carcinoma0 0 1 (6.7%) 0 1 (3.0%)
Nephrolithiasis 0 0 0 1 (33.3%) 1 (3.0%)
Osteoarthritis 1 (8.3%) 0 0 0 1 (3.0%)
Pneumonia 0 1 (33.3%) 0 0 1 (3.0%)
Pneumonia Aspiration 1 (8.3%) 0 0 0 1 (3.0%)
Retinal Detachment 2 (16.7%) 1 (33.3%) 1 (6.7%) 1 (33.3%) 5 (15.2%)
Retinopathy Proliferative 1 (8.3%) 0 0 1 (33.3%) 2 (6.1%)
Suicide Attempt 1 (8.3%) 0 0 0 1 (3.0%)
Thoracic Vertebral Fracture 0 1 (33.3%) 0 0 1 (3.0%)
Urinary Tract Infection 0 1 (33.3%) 0 0 1 (3.0%)
Urosepsis 0 1 (33.3%) 0 0 1 (3.0%)
Note: A treatment -emergent AEwas defined as any event that started during or after the administration of study 
treatment. A subject experiencing the same AEmultiple times is counted once within the corresponding preferred 
term. Percentages are based on t he number of treated subjects. 
There were no clinically  significant changes in vital signs, physical examination, or clinical 
laboratory  parameters.
Safet y data available from this study  suggest that CNTO 2476 is without substantial toxicity  
when subretinal administration occurs without a retinal break. However, the iScience MDS is not 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
36
Status: Approved , Date: 15 December 2017suitable for further development, and an alternative approach to subreti nal delivery  will be 
required.
A single administration of CNTO 2476 did not appear to elicit an immune response. No relevant 
treatment group differences in shift changes were noted for positive antibody  titers. There were 
no clinically  meaningful changes in median values from baseline for antibody  titers within the 
treatment groups. One subject appeared to have pre-existing antibody  to CNTO 2476, and 
1subject had a de novo immunologic response to treatment with CNTO 2476. The presence of 
serum antibodies d irected against CNTO 2476 was not associated with ocular adverse or 
inflammatory events. 
There have been 3 deaths among the 33 treated subjects, 1 each of depression/suicide, cancer of 
the lung and chronic obstructive pulmonary  disease/pneumonia. None was considered to be 
treatment related.
1.2. Overall Rationale for hUTC Development and Delivery System Innovation
Geographic atroph yrelated to AMD is the most common cause of blindness in the developed 
world among persons over age 60; in the United States (US) alone, approximately  8  m illion 
persons age 55 or older have intermediate or advanced AMD, and the prevalence of GA
specificall y in person over age 40 is 0.8%, or approximately  970,000 individuals.10The 
prevalence of AMD and GA is similar in other developed nations and will increase with the 
aging of the population. There are currentl y no approved therapies for the treatment of the dry 
form of AMD, including GA. 
Human umbilical tissue cells are easily available without the need to obtain or manage 
differentiation of stem cells; they are fully  differentiated and have low potential for uncontrolled 
proliferation or teratoma formation; and they are rea dily expanded in vitro. Potency  and viability  
assay s are available to ensure quality  and consistency  of scaled up manufacturing. 
Both in vitro and in vivo data indicate that hUTCs have beneficial effects on RPE cells. As 
described above, hUTCs improve RPE phagocy tic function in vitro and in vivo, with 
corresponding improvement in vision the RSC rat model. HUTCs also appear to modulate 
oxidative stress and neuroplasticity , factors which are disordered in GA. 
Furthermore, Phase 1 human data suggest that sub retinal delivery  of CNTO 2476 improve vision 
by at least 15 letters in BCVA, as compared to a fellow -eye control, and this benefit appears to 
be maintained through Month 12.CNTO cells appear to be safe when delivered as intended. 
These findings strongly  support the further development of the therap y.
The safe delivery  of CNTO 2476 to the appropriate location is currently  the most important 
factor in the development of this program, and delivery  of viable cells in the subretinal space 
requires some type of surgical procedure . Experience in the clinic has shown that leakage or 
reflux of cells into the vitreous may lead to proliferation of cells with membrane formation with 
to traction and retinal detachment. Thus, delivery  of CNTO 2476 to the subretinal space without 
a break to the retina is of paramount importance. In the Phase 1 study , the iScience microcatheter 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
37
Status: Approved , Date: 15 December 2017delivery  system was used with an ab externo surgical approach. That approach was found to be 
challenging, requiring 2 operators, and resulting in anunacceptable rate of retinal tears and 
retinal detachments. That surgical approach is inadequate for further development.
Given the limitations of the iScience MDS, a newly  developed Delivery  Systemwill be utilized 
in thisPhase 2b study . The Delivery  System was developed to facilitate delivery  of CNTO 2476 
cells to the targeted perimacular subretinal delivery  site via a suprachoroidal approach .The 
suprachoroidal surgical procedure was selected and the new Delivery  System was developed 
with the goal of improving the delivery  device and procedure usability  and facilitating the safe 
targeted delivery  of CNTO 2476 .
The Delivery  System is being developed in accordance with 21 Code of Federal Regulations 
(CFR)Part 4, Current Good Manufacturing Practice regul ations for Combination Products, 
including 21 CFR Part 820.30, Medical Device Design Controls. Verification and validation 
testing for the device portion of the combination product will beperformed prior to this clinical 
study to demonstrate that the devi cesperform safely  according to theintended use of infusing cells.
The Delivery  System is investigational in this clinical study  for the intended use of delivery  of 
CNTO 2476 cells. This is a first- in-human clinical use of an innovative Delivery  System. As such,
the proposed Phase 2bstudy  will employ  a Safety Run-in Phase as a Delivery  System pilot study , 
prior to randomization of subjects into the controlled Double -masked Treatment Phase of the 
study .
1.3. The Cell Delivery System
The Delivery  System is investigational for the intended use of delivering CNTO 2476 cells in 
this study . The Delivery  Systemwasdeveloped to facilitate delivery  of CNTO 2476 cells to the 
targeted perimacular subretinal delivery  site via a suprachoroidal approach. The devices that 
comprise the Delivery  System are described in the Investigational Product Manual.
2. OBJECTIVES A ND HYPOT HESES
2.1. Objectives
Primary Objectives
The primary  objective of the open -label Safet y Phase is to evaluate the safet y and performance
profile of the supr achoroidal surgical approach and the Delivery  System. 
Major Secondary Objectives
The major secondary  objectives of this study  are the following: 
to assess the safet y and performance profile of the Delivery  System, the safet y and 
tolerability  of the supra choroidal surgical approach, and the safet y and tolerability  of 
CNTO 2476 cells in the open-label Safet y Run -in Phase .
to assess the effects of CNTO 2476 on anatomic correlates of treatment, including change in 
the area of GA
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
38
Status: Approved , Date: 15 December 2017to assess the effects of CNTO 2476 on additional and alternative efficacy  outcomes 
including duration of clinical response.
2.2. Hypothesis
The primary  hypothesis of theopen label safet y phase of this study  is that the novel subretinal 
delivery  system is sufficiently  safe and usable to deliver cells to the subretinal space. An 
additional hy pothesis is that palucorcel is safe and well tolerated when delivered as a single dose 
to the subretinal space.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a multicenter Phase 2b study . A target of approximately  21 subjects will be enrolled in 
this study . This protocol amendment represents a significant reduction in scope and duration of 
the study  based on the sponsor ’s decision to discontinue the pal ucorcel development program.
The study  includes only an initial open -label safety  phase . 
The target population will be subjects at least 55 years of age and no older than 90yearswith a 
confirmed diagnosis of bilateral GA of the macula secondary  to age-related macular 
degeneration, with associated vision loss, confirmed within 45days prior to initial randomization 
by the central reading center using fundus and/or autofluorescence photography . In subjects with 
neovascular AMD in 1eye, the eye with GA must be the worse eye. In subjects with bilateral 
GA and the vision between both ey es is not clinically equal, the ey e with the worse vision will be 
treated in order to minimize risk to the subject’s vision. In cases where the BCVA of the 2eyes 
is clinically equal, the eye with the larger GA as demonstrated on the imaging studies will 
become the stud y eye.
The Safet y Run-in Phase consists of approximately  21subjects (the first 3subjects at each of 
approximately  8sites) who will first be enrolled in an open-label assessment of the safety  profile 
of the procedure and the Delivery  System.The first 3 subjects at the first 8sites (approximately 
21subjects in total) will be the initial Safet y Cohort. A minimum of s even different surgeons are 
required to ensure most of the possible failure modes will be identified.16Enrollment will be 
activel y managed to ensure that experience and learning from earlier procedures are promptly  
transferred to the subsequent procedures, and to ensure that an appropriate number of subjects 
are enrolled at the time of the planned safet y assessments.
The safet y profile of the procedure and the Delivery  System will be assessed after the first 
21subjects (the initial Safety  Cohort) have been treated and followed for a minimum period of 1
month. An external Data and Safet y Monitoring Board (DSMB )will be commissioned for this 
study .The 2ndSafet y Cohort and thedouble blind portion of this study have been eliminated 
from this study  protocol.
The study  will consist of a 12-month acute phase, followed bya 2-year maximum duration 
follow -up period ( 3years total) for all subjects. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
39
Status: Approved , Date: 15 December 2017Screening Phase
All subjects will be required to give a written informed consent to participate in the trial. In a 
separate consent, subjects will have the option of providing a DNA sample for genot yping. 
Subjects may also have the option of donating their ey esfor histological evaluation post mortem , 
using a supplemental informed consent.
Subjects may be screened over a period of up to 45days prior to treatment to assess their 
eligibility  for the study  based onthe inclusion and exclusion criteria defined for this study . 
Patient eligibility  will be determined based on the results of 2 BCVA examinations performed at 
the screening visits. These examinations can occur on the same day or subsequent days. The 
better of the 2 logMAR BCVA scores will be used for eligibility  and randomiza tion. These 
examinations should be performed prior to any other ocular study  procedures that would 
interfere with vision assessments such as dilation or bright light assessments .
Visual acuit y tests, contrast sensitivity , MN Read , intraocular pressure (IOP), slit lamp 
examinations, microperimetry, fundus photograph y, SD-OCT, fundus autofluorescence, 
fluorescein angiograph yand dilated fundus examination readings will be carried out on all 
subjects . At baseline, axial length will be recorded in the CRF. Ind ocyanin green angiograph y
will be performed on all subjects unless discussed with the S ponsor . 
Other assessments will include medical history , genomic material from consented subjects, 
demographics, a targeted physical examination, vital signs, routine laboratory  and routine 
urinaly sis In addition blood samples for immunogenicity , medication history , concomitant 
medications, and the NEI-VFQ -25and the Near Vision subscale , and the SF-36and FRI,will be 
collected.
Additional details of the screening phase are provided in Section 9.1.1.1 (Screening Phase). 
Open -label Safety Run -in Phase
A minimum of the first 3 eligible subjects at each center will receive active treatment in an 
uncontrolled, open-label Safety  Run-in Phase to assess the safety  of the surgical procedure and 
Delivery  System, and to ensure the familiarit y of the surgeons with the Delivery System and the 
procedure . The first 21 subjects from the designated Safet y Cohort study  sites will comprise the 
initial Safety  Cohort. Enrollment into the safet y Run-in Phase will be staggered across sites to 
ensure that the outcomes and learnings from earlier procedures can be transferred to all 
participating surgeons who will perform subsequent procedures. A 1-week interval for 
information sharing between the first few subjects is appropriate since most procedure -related 
AEs are expected to be apparent w ithin hours of surgery . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
40
Status: Approved , Date: 15 December 2017Long -term Follow -UpPhase
After the 12-month acute phase of the study , subjects will be followed every  6  m onths for 
2years in the Long -term Follow -up Phase of the study ,as shown in the Time and Events 
Schedule (see Table 2 ).
A DSMB will be established to monitor study  data on an ongoing basis to ensure the continuing
safet y of the subjects enrolled in this study .Refer to Section 11.6, Data and Safety  Monitoring 
Board , for details. The committee will meet periodically  to review interim study  data. After the 
review, the DSMB will make recommendations regarding the safet y and continuation of the 
study . The details will be provided in a separate DSMB charter.
3.2. Study Design Rationale
This protocol amendment represents a significant reduction in the scope and duration of the 
planned trial, based on thesponsor’s decision to discontinue the palucorcel development 
program. The intent of the current study  design is to ensure adequate long-term safet y follow -up 
of the subjects previously  enrolled, while minimizing the visit burden on subjects and 
investigators.
The target population for this study  is adult subjects (at least 55 years of age and no older than 
90years) with GA of the retina secondary  to age related macular degeneration, with a baseline 
visual acuit y of approximately  logMAR 0.6 (20/80) to logMAR 1.6 (20/800) . The best visual 
acuity of logMAR 0.6 (20/80) was selected because in this range, vision is compromised to a 
degree that restricts certain activities of daily living, and the potential benefit to the subjects 
justifies risks associated with the procedure and treatment. 
A critical requirement of the program is the ability to deliver viable cells safely  and efficientl y to 
the subretinal space, without damaging the retina, and without leakage of cells into the vitreous. 
Currently , there is no alternative to surgical delivery . Previous studies using a transvitreal 
approach or an ab externo surgical approach have led to an unacceptable rate of retinal tears and 
detachments. The new suprachoroidal surgical procedure was selected and the new Delivery 
System desig ned with the goal of simplify ing the procedure and facilitating the safe targeted 
delivery  of CNTO 2476.
The use of the Delivery  Systemin the Safety  Cohort is a first-in-man study  and AEs and device 
quality  will be assessed by  an independent DSMB after th e first 21 subjects have been treated (or 
sooner, if a stopping threshold is reached).
Dose Selection
The breadth of the dose range is constrained by the cell densit y during cryopreservation and the 
minimal volumes that can be accuratel y administered to minimize the detachment at the 
subretinal injection site; the feasible doses were all studied in the Phase 1/2a study . The greatest 
experience to date is with the 3.0 x 105cell dose (15 subjects). Although that dose was 
administered in a 27 µL volume in the prior study , there is no reason to believe that the volume 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
41
Status: Approved , Date: 15 December 2017of administration is relevant to either safety  or efficacy ; the AEprofile for this dose/volume 
combination is comparable to a smaller dose ( 6.0 x 104cells) given in a 50 µL volume.
3.2.1. Control
The open- label phase of this study  does not require a control group. 
3.2.2. Masking
The open- label phase of this study  does not require masking .
3.2.3. Randomization
The open- label phase of this study  does not require randomization.
3.2.4. Primary Outcome Measure
Change in BCVAis considered meaningful to patients and has been accepted by the US Food 
and Drug Administration (FDA )as an approvable endpoint in trials of therapeutic agents for 
AMD. In addition, BCVA reflects holistically  both the potential benefits (gain in visua l acuit y 
from therap y) and harms (loss of visual acuit y due to AEs). Assessment of BCVA is known to be 
partly  effort-dependent, and every  effort will be made to standardize these assessments. The 
Early Treatment Diabetic Retinopathy  Study (ETDRS )chart at 4 meters is considered the ‘gold 
standard’ for visual acuity  testing in clinical research for its phy sical and statistical properties.
4. SUBJECT POPULA TION
Approximately  100 subjects will be screened to enroll approximately 21 subjects in the 
open -label safet y phase of this study .
Screening for eligible subjects will be performed within 45days before administration of the 
treatment .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the following 
2 subsections. Ifthere is a question about the inclusion or exclusion criteria below, the investigator 
should consult with the appropriate sponsor representative before enrolling a subject in the study . 
For a discussion of the statistical considerations of subject select ion, refer to Section 11.2, 
Sample Size Determination.
4.1. Inclusion Criteria
Each potential subject must satisfy  all of the following criteria to be enrolled in the st udy. 
1. Subject must b e aman orwoman at least 55 yearsto90years of age, inclusive.
2.2 D iagnosis of GA secondary  to AMD confirmed within 45days prior to initial 
randomization. Diagnosis verified by the central reading center using fundus 
photographs and including the following;
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
42
Status: Approved , Date: 15 December 2017The study eyes must have at least 1GA lesion that involv esthe fovea, and a 
Macular Photocoagulation Study  (MPS) disc areas (DA) of 0.5and 7(1MPS 
disc area equivalen t to 2.54 mm2on the retina) determined by screening images of 
fundus autofluorescence photographs as calculated by the reading center . If GA is 
multifocal, at least 1lesion must be 0.5 DA .
oIn the Safety  Run-in Phase only, DA of 0.5 with no maximum specified 
area, as long as the criteria below for photography  can be met and the 
surgeon determines that the GA size will not impede cell delivery .
Geographic atroph ymust be able to be photographed in its entirety  and may be 
contiguous with peripapillary  atroph y. 
Retinal photograph s, fundus autofluorescence images, and angiography  of 
sufficient quality , allowing assessment of the macular area according to standard 
clinical practice, can be obtained.
The imaging center must be able to delineate and confir m peripapillary atrophy  
with fundus photograph y and fundus autofluorescence. 
Images must include the central field 1, 2, and 3 field images as defined by the 
University  of Wisconsin standards as well as a supero -temporal image to capture 
the subretinal in jection area if possible.
3.2 Study eyes will have a BCVA of 20/80 to 20/ 800 ( ETDRS logMAR value 0.6-1.6). The 
treatment eye will be that with the worse BCVA at screening .If BCVA is clinicall y 
equivalent, the ey e with the larger GA determines the study  eye. 
4. Subject is a suitable candidate for ophthalmologic surgery , is willing and able to comply  
with the surgical procedure, scheduled visits, treatment plan, laboratory  tests and other 
study  procedures. Subject has met criteria of the surgery  center anti-coagulation 
protocol, if applicable.
5. Female subjects must be post-menopausal with last menses 12 months prior, or longer , 
ORa measured follicle stimulating hormone 26mIU/mL .
6. Male subjects must be sterile or willing to use 2approved methods of contraception 
from first day post-operatively  to 3 months post-operativel y (approved methods of 
contraception include condom with spermicide, a sterile sexual partner, a sexual partner 
using oral or implantable contraceptive or an intrauterine device with spermicide, a 
diaphragm with spermicide, or cervical cap with spermicide).
7. Each subject must sign an informed consent form (ICF) indicating that he or she
understands the purpose of and procedures required for the study  and are willing to 
participate in the study .
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
43
Status: Approved , Date: 15 December 20174.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study .
1.2 Subject h as a history  of neovascular (“wet”) AMD in the treatment eye,including any 
evidence of retinal pigment epithelium rips orevidence of subretinal or choroidal 
neovascularization or fluid .In cases where imaging is inconclusive, review of the case 
with the study  site, considering history  and imaging will determine eligibility .History  
or evidence of neovascular AMD in the fellow eye is allowed, if anti-vascular 
endothelial growth factor (VEGF)therapy  has not been required for at least 8 weeks 
prior to screening.
2. Geographic atroph y secondary  to an y causes other than AMD in either ey e
3 A diagnosis of glaucoma with an IOP 25 mmHg while being treated with an ocular 
hypotensive drug. Treatment should be no more than 1drug preparation /combination , 
which can contain 1 or 2 ocular hypotensive active ingredients ; subjects receiving more 
than 2ocular hy potensive active ingredients are exclude d. Note: subjects with a diagnosis 
of ocular hypertension (not glaucoma) are eligible to participate whether or not they are 
being medicall y treated.
4. Nuclear sclerotic cataract, cortical spoking, posterior subcapsular cataract above 
Grade 2 per Age-Related Eye Disease Study  (AREDS) scale or any other 
ophthalmologic condition that reduces the clarit y of the media that, in the opinion of the 
investigator or reading center, interferes with ophthalmologic examination (eg, corneal 
abnormalities, inadequate pupillary  dilation), surgery  or imaging in the study  eye
5. Myopia >-8 diopters and subjects with >4 diopters of astigmatism, and >+10 diopters of 
hyperopia. Note: clinical evidence of retinal degeneration secondary  to pathological 
myopia will exclude the subject as will a scleral ectasia with or without high my opia.
6. Evidence of other significant ophthalmologic disease (eg, glaucoma, intraocular 
inflammatory  disease, diabetic retinopath y, Stage II, III, or IV macular hole, clinically  
evident vitreoretinal traction, choroidal or retinovascular disease, cystoid macular 
edema , significant epiretinal membrane , significant blepharitis, keratitis, conjunctivitis ,
or staphy loma )in the study  eye
7.2 Previous treatment for confirmed AMD (dry or wet) in the study  eye with treatments
other than antioxidant or zinc supplements (eg, AREDS1 or AREDS2 formula) or other 
oral vitamin supplements . Subjects who have received anti-VEGF treatment without a 
confirmed diagnosis of wet AMD or who have participated in previous studies for AMD 
may be considered eligible if these treatments/study  participation were given at least 
one y ear prior to enrollment.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
44
Status: Approved , Date: 15 December 20178.2 Previous intraocular surgery  within 3months prior to screening in either eye. Previous 
treatment with Visudy ne®, external -beam radiation therap y, or transpupillary  
thermotherap y in the study  eyeat an y previous time point.
9. Previous laser photocoagulat ion in the study  eye (peripheral laser for treatment of a tear 
is allowed if more than 6 months prior to screening except when, in the opinion of the 
surgeon, this would hamper the suprachoroidal cannulation procedure in the study  eye)
10. Previous vitrec tomy , retinal detachment repair, submacular surgery , other surgical 
interventions targeting AMD, scleral buckling or glaucoma filtration surgery  or any 
other extraocular or orbital procedure in the study  eye that, in the opinion of the 
surgeon, would hampe r the suprachoroidal cannulation procedure in the study  eye
11. History  of choroidal or scleral rupture in either study  or fellow eye due to uveitis 
(previous trauma in the study  eye or fellow eye in the case of good vision in that eye is 
not an exclusion criterion)
12. Uveitis or other intraocular inflammatory  disease within past 3 months
13 Active infections of the anterior segment
14. Keratoconus, penetrating keratoplast y, Descemet's stripping endothelial keratoplast y 
(DSEK), radial keratotomy  (RK), Laser -assisted in situ keratomileusis (LAS IK) in the 
study  eye
15. Monocular subjects
16. Subject has known allergies, hypersensitivity , or intolerance toCNTO 2476 or its
excipients (refer to Investigator's Brochure)
17. Medica lly not qualified for monitored anesthesia care intravenous sedation
18. Previous cell therap y other than standard blood and platelet transfusions
19. Subject has taken any disallowed therapies as noted in Section 8, (Prestudy  and
Concomitant Therap y) before the planned first dose of treatment
20.1 Subject has received an investigational drug (including investigational vaccines) within
30daysbefore th e planned first dose of treatment
21. Active malignancy  (requiring therapy ) or history  of malignancy  requiring therapy  
within 2years prior to Day 1 (with exception of cases of basal cell and squamous cell 
carcinoma of the skin)
22. History  of human immunodeficiency  virus (HIV) disease
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
45
Status: Approved , Date: 15 December 201723. Significant cognitive impairment that interferes with a subject’s ability  to participate 
with the testing regimen
24. History  of organ or bone marrow transplants
25. History  of alcohol or drug abuse within past 2 years
26. Significant hepatic dysfunction (aspartate aminotransferase [AST] or alanine 
aminotransferase [ALT] >3x upper limit of normal [ULN]),or significant renal 
dysfunction (estimated creatinine clearance 30mL/min) ,or on renal dial ysis
27. Signif icant uncorrectable coagulopath y, thrombocytopenia (platelets <100 x 103/µL) or 
other significant bleeding risk. Note: subjects on an anticoagulant therapy  should be 
considered at low risk for new thromboembolic events, and must agree to stop all 
anticoagulation therap y prior to surgery, as follows:
Warfarin  5 day s
Aspirin 7 day s
Oral Factor Xa inhibitors 3 day s (or longer, depending on renal function)
Dabagatran  3 day s
Low molecular weight heparin 1 day
Clopidogrel and ticagrelor 5 day s
Prasugrel  7 day s
Ticlopidine 10 day s
28 Uncontrolled systemic hypertension on the day of surgery , defined as a systolic blood 
pressure 180mm Hg. Note: if the subject’s systolic blood pressure can be controlled 
later b y the subject’s medical doctor, elig ibility  for surgery  can be re -assessed. 
29. Subject h as any condition for which , in the opinion of the investigator, participation
would not be in the best interest of the subject (eg, compromise the well- being) or that
could prevent, limit, or confound the protocol- specified assessments
30. Subject i s an employ ee of the investigator or study  site, with direct involvement in the
proposed study  or other studies under the direction of that investigator or study  site, as
well as famil y members of the employ ees or the investigator
31. Known allergy to iodinated contrast d yes
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory  results or receipt of addi tional medical records ) 
after screening but before the first dose of treatment is given such that he or shenolonger meet s
all eligibility  criteri a, then the subject should be excluded from participation in the study . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
46
Status: Approved , Date: 15 December 2017Section 17.4, Source Documentation, describes the required documentation to support meeting 
the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
a. A man who is sexually active with a woman of childbearing potential must use a
double -barrier method of birth control (ie, male condom, female diaphragm or cervical
cap, or condom) and all men must also not donate sperm for3months after receiving 
the last dose of study  drug.
b. Subjects must agree to defer blood, blood component, or tissue donation until 12 months 
post treatment
5. TREA TMENT ALLOCA TION AND MASKING
Treatment Allocation
All subjects in the Safety Cohort will receive the same dose of 3.0 x 105cells in 50 µL .
Masking
Masking is not applicable to the open -label safet y phase of this study.
6. DOSA GE A ND A DMINISTR ATION
6.1. Open-label Safety  Run -in Phase
Subjects in the Safety Run-inPhase will receive 3.0x 105cells in 50 µL dosing volume .
CNTO 2476 will be delivered using the custom- designed Delivery  System and surgical 
procedure.
Each subject in the Safety  Run-in Phase will receive a single subretinal administration of 
CNTO 2476. A high-level overview of the procedure for administering thesingle dose of 
CNTO 2476 in 1 eye is described below:
An eyelid speculum will be placed and a chandelier is inserted targeting illumination of the 
superiotemporal quadrant
A trap-door conjunctival incision will be made in the superiotemporal quadrant to expose 
the sclera
With aid of measuring template, a “suture loop” will be created between the limbus and the 
sclerotomy  site
A sclerotom y incision will be created approximately 3mm in length
The cannula will be insert edthrough the suture loops, through the sclerotomy , and 5mm 
into the suprachoroidal space
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
47
Status: Approved , Date: 15 December 2017The retina will be visualized through the pupil and the cannula is advanced to the target 
location superior to the macula
Under direct visualization of the cannula tip, the needle will be advanced and a small saline 
entry  bleb is created
When successful subretinal entry  has been established, the surgeon will administer 50 µL of 
CNTO 2476 cells subretinally
The needle will be withdrawn, and the cannula removed from the suprachoroidal space
The suture loops are removed and the sclera and conjunctiva will be closed
A detailed description of the surgical procedure will be available andupdated as a part of the 
physician training materials.
7. TREA TMENT COMPLIA NCE
The investigational product will be administered subretinally  as a single dose bythe retinal 
surgeon . The administration of the investigational product will take place in an operating room 
using the Delivery  System . Compliance will not require an y activity  by the subject.
8. PRESTUDY AND CONCOMI TANT THERAPY
All pre-study  therapies administered up to 30days before first dose of treatment must be 
recorded at screening.
Peri-operative (subconjuntival vancomy cin) and post-operative (PRED FORTE®and Polytrim®) 
or equivalent medication regimens are required in order to have standardization in treatments 
across sites.
Systemic concomitant therapies must be recorded throughout the study  beginning with start of 
treatment to 1year after the last dose of treatment .Systemic therapies for eye disease or any 
concomitant therapies given by ophthalmic routes must be recorded for the entire 3years.
Concomitant therapies associated with an SAE should also be recorded for the entire 3years.
All therapies (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements different from the study  drug )must be recorded in the eCRF .
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
Prohibited Concomitant Medications
The following are prohibited in the 3 0 day s prior to dosing, and discouraged thereafter:
Hydroxy chloroquine (unless taking less than 6.5 mg/kg/day ) 
Chloroquine (unless taking less than 3 mg/kg/day)
Thioridazine 
Chlorpromazine
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
48
Status: Approved , Date: 15 December 2017Tamoxifen, 
Isotretinoin
Clofazimine
Cisplatin
Carmustine 
Systemic corticosteroids 20mg/day  prednisone (or equivalent) for > 14 day s. 
9. STUDY EVALUATIONS
9.1. Study Procedures
9.1.1. Overview
The TIME AND EVENTS SCHEDUL ESis a summary  of the frequency  and timing of efficacy , 
immunogenicit y, pharmacogenomic, PROs, and safet y measurements applicable to th estudy .
The Time and Events Schedule lists the dayassoci ated with each visit until Day 15, and then the 
month associated with each visit through Month 12, and Month 18 through Month 36 of the 
long-term follow -up phase . From Day 7 through Month 6a visit window of ±3business days 
will be allowed; for the Month 12 visit, a visit window of ±7 days will be allowed. From 
Month 18 through Month 36 a visit wind owof ±2weeks (14days) will be allowed. The data on 
the visit should alway s be calculated from the baseline visit, and not from the prior visit.
All visit-specific, PRO assessments should be performed before any tests, procedures, or other 
consultations for that visit to prevent influencing subject perceptions .
The BCVA, l ow luminance BCVA (LLBCVA) ,and contrast sensitivity  will all be performed 
using a valida ted testing protocol . BCVA is the best vision one can achieve with best correction
ETDRS acuity  testing , and is a done using a standard ETDRS chart for visual acuit y testing.
The MN Read will be used to determine reading speed (RS, [measured in characters per 
minute]), critical print size (CPS, [measured in logMAR]), as well as RA (measured in 
logMAR). 
Microperimetry  will be performed using the MAIA2 system measuring the sensitivity  in 
decibels . 
New technology  assessments, eg,Optical Coherence Tomography  Angiograph y (OCT- A) and 
intraoperative Optical Coherence Tomography ,may be performed at the surgeon or 
investigator’s discretion but do not substitute for any of the mandato ry evaluations listed in this 
protocol.
A standard full ophthalmology  examination will be performed and will include IOP, slit lamp 
examinations, and dilated fundus examinations. The order of multiple ophthalmologic 
assessments within 1 protocol time point will be the same throughout the study .
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
49
Status: Approved , Date: 15 December 2017The following imaging data will also be collected and analyzed by the Digital Angiography 
Reading Center (DARC): 
fundus photograph y
SD-OCT
fundus autofluorescence 
fluorescein angiograph y 
Indocy anin green angiograph y 
The NEI-VFQ -25and the Near Vision subscale, and the SF-36 contained in the appendices, will 
be used in the study to evaluate quality  of life . 
Blood may be drawn using a cannula or by other venipuncture. The exact times for each blood 
draw or assessment will be recorded. The total volume of blood to be collected from each subject 
is 107.4 mL. For each subject the amount of bloo d drawn is summarized in Table 4 .
Table 4: Volume of Blood to be Collected From  Each Subject
Time Point for Blood Collection Amount of Blood Collected (mL)
Screening 16.3
DNA Collection 8.5
Day 7 10.0
Day 15 10.0
Week 4 16.3
Month 2 10.0
Month 3 10.0
Month 6 10.0
Month 12 16.3
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples .
A DSMB will be established to monitor study  data on an ongoing basis to ensure the continuing 
safet y of the subjects enrolled in this study .Refer to Section 11.6,Data andSafety  Monitoring 
Board for details. The committee will meet periodically  to review interim study  data. After the 
review, the DSMB will make recommendations regarding the safet y and continuation of the 
study . The details will be provided in a separate DSMB charter.
9.1.1.1. Screening Phase
Prior to the full study  screening phase , optional BCVA pre-screening may be done to evaluate 
subjects for BCVA eligibility . In this case, subjects must sign an optional pre-screening ICF 
prior to testing. The site will determi ne results of local testing and indicate if the subject is 
eligible for full study  screening. If the BCVA test indicates the subject meets the necessary  
eligibility  criteria, he or she will enter the full screening phase under the full study  ICF for 
determ ination of full study  eligibility .
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
50
Status: Approved , Date: 15 December 2017All subjects will be required to give written informed consent to participate in the trial. In a 
separate consent, subjects will have the option of providing a DNA sample for genot yping. 
Subjects will also have the option of donating their ey es for histological evaluation post mortem , 
using a supplemental informed consent.
After giving written informed consent, subjects may be screened over a period of up to 45days 
prior to treatment to assess their eligibility  for the study  according to the inclusion and exclusion 
criteria defined for this study . The screening process may occur over a period of days. If a 
subject fails screening for a reason determined to be temporary, they may be rescre ened to 
determine eligibility  by following these criteria: 
Elevated IOP, uncontrolled blood pressure, elevated liver enzy mes , decreased platelet s and 
decreased renal function, if correctable with treatment or time
Acute infections, after successful treatment
Time -bound restrictions (e.g., Exclusions 8, 9, 12, 20, 21 and 25) after an appropriate 
waiting period such that the exclusion no longer applies
Use of prohibited prior medications, after an appropriate wa iting period.
Potential patients who fail screening for visual acuity , retinal anatomy  or other ocular findings 
should not be rescreened. Any rescreening request not mentioned here should be discussed with 
the study  Medical Monitor. For rescreened subject s, imaging studies do not have to be repeated  
if performed in the 60 days prior to start of new screening. For rescreened subjects, clinical 
laboratory  exams (bloodwork) do not have to be repeated if performed in the 45days prior to 
start of the new scree ning. 
Patient eligibility  will be determined based on the results of 2 BCVA examinations performed at 
the screening visit. These examinations can occur on the same day or subsequent days. The 
better of the 2 logMAR BCVA scores will be used for eligibility and randomization. These 
examinations should be performed prior to any other ocular study  procedures that would 
interfere with vision assessment such as dilation or bright light assessments . 
Visual acuit y tests, contrast sensitivity , MN Read , IOP, slit lamp examinations (including lens 
mobility  examination), microperimetry , fundus photograph y, SD-OCT, fundus autofluorescence, 
fluorescein angiograph yand dilated fundus examination readings will be carried out on all 
subjects. At baseline, axial length will be recorded in the CSF. Indocy anin green angiography 
will be performed for all subjects unless discussed with the Sponsor .Medical history , genomic 
material from consented subjects, demographics, physical examina tion, vital signs, routine 
laboratory  and routine urinaly sis data will also be collected during the screening visit. In 
addition, blood samples for immunogenicity , medication history , and the NEI-VFQ -25and Near 
Vision subscale , SF-36and FRI , will be done during the screening visit. Changes in conc omitant 
medications will be recorded on Day 1. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
51
Status: Approved , Date: 15 December 20179.1.1.2. Open -label Safety  Run -in Phase
The study  will begin with a minimum of 7 surgeons performing approximately  3 open -label 
procedures to complete an initial Safety  Cohort of 21 subjects. A minimum of 7surgeons were 
chosen for the Safet y Cohort based on the amount of users needed to identify  complications with 
a surgical procedure and Delivery  System. According to usability  standards for medical devices, 
5 to 8 surgeons performing 1to 5 procedures at each site for a total of 21 procedures find 
between 7 5% and 90% of usability  defects .16
After a total of 21 subjects are enrolled in the study , a safety review of the Delivery  System and 
procedure will be performed . The data will be reviewed in a meeting with the surgeons, Principa l 
Investigators, and the DSMB . The data will be assessed in the context of the predefined stopping 
rules described in the DSMB Charter .Events of special interest are choroidal hemorrhage, 
endophthalmitis or infections, retinal detachments, leakage of cells into the vitreous/need for 
vitrectomy , significant loss of vision defined as loss of ≥15 letters compared to baseline inthe 
first month post -surgery , and failure to deliver cells/device failure.
9.1.1.3. End of Treatment or Early  Withdrawal
Every  attempt should be made to follow subjects through their final visit (Month 3 6). In the 
event that a subject prematurel y discontinues fro m the study  for any  reason, an end-of-study visit 
should be completed (see Section 10.2 for criteria for treatment discontinuation). Assessments 
and procedures to be completed at the end-of-study visit are listed in the Time and Events 
Schedule (Table 2). 
If a subject withdraws from the study  due to an AE, every  reasonable attempt will be made to 
follow the subject until the AE resolves or until the investigator, in conjunction with the sponsor, 
deems the AEto be chronic or stable. All SAEs will continue to be followed as instructed in 
Section 12.3.2 .
9.1.1.4. Long -term Follow -up Phase
Subjects who complete the 12-month acute phase of the study  will be followed every  6 m onths
for 2years in the Long -term Follow -up Phase ,as indicated in the Time and Events Schedule 
(Table 2 ).
9.2. Efficacy
9.2.1. Evaluations
Subjects who successfully  complete the screening visit will present to the clinical site on Day 1 
(pre-operative visit on the treatment day), at which time CNTO 2476 will be administered. The 
Delivery  Systemwill also be assessed at this time. All study  assessment sarelisted in the Time 
and Events Schedule ( Table 1and Table 2 ).
9.2.1.1. Primary  Efficacy  Measure
The primary  efficacy  measure will be the BCVA testing performed after refraction and under 
standardized photopic lighting conditions and distance using an ETDRS logMAR chart.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
52
Status: Approved , Date: 15 December 20179.2.1.2. Secondary  Efficacy Measures
The BCVA will be assessed at the 6-and 12-month visits to evaluate the major secondary  
endpoints described in Section 9.2.2 .
An additional assessment of growth rate of GA lesion documented at baseline to 12 months will 
be performed. Lesion size will be determined b y the DARC will also be performed .
9.2.2. Endpoints
Primary Endpoints
The endpoints of the open -label SafetyRun-inPhase are all related to the objective of evaluating 
the safet y profile of the procedure , Delivery  System , and of the implanted hUTC cells.
Major Secondary Endpoints
Proportion of subjects losing 15BCVA letters from baseline at 12 months following 
treatment with CNTO 2476
Change in mean number of BCVA letters from baseline at the 6-and 12-month visits
following treatment with CNTO 2476
Growth rate of GAlesion documented at baseline to 6 and 12 months following treatment 
with CNTO 2476. The a rea of GAis determined based primarily  on fundus autofluorescence
as well as fluorescein angiograph yand fundus photos
9.3. Immunogenicity
The evaluations, analytical procedures, and immunogenicity  assessments done are described in 
the sections following . Additional instructions sample handling and disposition are provided ina 
separate laboratory  manual . 
9.3.1. Evaluations
Venous blood samples will be collected by the investigator site for immunogenicity  assessment. 
The measurements will be taken at screening, Day 7 and 15, Week 4, Month 2, 3 6, and 12. This 
will allow dy namic monitoring of the serum antibody  levels. Additional information on the blood 
volumes to be collected is provided in the Time and Events Schedule ( Table 1).
Serum antibody  levels pre-and post-administra tion of CNTO 2476 will be assessed by 
co-incubating subject serum samples and CNTO 2476 . An antibody  detection system will then 
be added and the bound serum antibodies are measured via flow cytometry .The titer of 
confirmed positive samples will be reporte d.
The serum will be separated at the investigator site laboratory  and transferred to the appropriate 
storage vials supplied in the sample kit. The tubes will be stored at the prescribed temperature 
and shipped to the lab oratory /storage of the Contract Research Organization (CRO), according to 
instructions. The CRO will send the samples to the laboratory assessing the serum antibodies on 
a monthly  basis. The laboratory  will assess the serum antibody  levels and deliver the results to 
theCRO . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
53
Status: Approved , Date: 15 December 20179.3.2. Analytical Procedures
Serum samples will be screened for the presence of antibodies binding to CNTO 2476. The 
detection and characterization of antibodies to CNTO 2476 will be performed using a validated 
assay  method by or under the supervision of the sponsor. Other analyses may be performed to 
verify  the stability  of antibodies to CNTO 2476 and/or further characterize the immunogenicity 
of CNTO 2476.
All samples collected for detection of antibodies to CNTO 2476 will also be evaluated for 
CNTO 2476 serum c oncentration to enable interpretation of the antibod y data.
9.3.3. Immunogenicity  Assessments
Blood samples for determination of antibodies to CNTO 2476 will be collected from all subjects 
according to the Time and Events Schedule. Samples should also be collecte d at the final visit 
from subjects who are withdrawn from the study .Blood samples will only be collected during 
study  assessments f or the safet y run-in phase and the randomized double -masked treatment 
phase from screening through the Month 12 postoperativ e visit. 
9.4. Intraoperative Delivery S ystem and Procedure Evaluations
The Delivery  Systemis designed to access the suprachoroidal space and the subretinal space, and 
to deliver the cells subretinal ly. 
In order to evaluate the safet y of the Delivery  System for the intended use of delivering 
CNTO 2476 cells, device -related safet y information will be collected. Relevant ophthalmic AEs 
will be evaluated. In addition, specific device performance data will be collected .
9.5. Safety  Evaluations
Details regarding the DSMBare provided in Section 11.6.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the valuations of safety and tolerability  according to the time points 
provided in the Time and Events Sched ule(Table 1and Table 2) and as described in the 
following sections.
9.5.1. Adverse Events
Adverse events will be reported by the investigator or the subject (or, when appropriate, by a 
caregiver, surrogate, or the subject's legall yacceptable representative) for the duration of the 
study . Adverse events will be followed by the investig ator as specified inSection 12, Adverse 
Event Reporting.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
54
Status: Approved , Date: 15 December 20179.5.2. Clinical Laboratory  Tests
Blood samples for serum chemistry  and hematology  and a random urine sample for urinaly sis
will be collected. The investigator must review the laboratory  report, document this review, and 
record any clinicall y relevant changes occurring during the study  in the AEsection of the CRF. 
The laboratory  reports must be filed with the source documents.
The following tests will be performed by the central laboratory (Covance Laboratories), and by 
the local laboratory (Catalent) for immunology  assessments :
Hematology  Panel
hemoglobin platelet count
hematocrit prothrombin time (PT)
red blood cell (RBC) count partial thromboplastin time (PTT)
white blood cell (WBC) count
with differential
Serum Chemistry  Panel
sodium total bilirubin
potassium alkaline phosphatase
chloride lactic acid deh ydrogenase (LDH)
blood urea nitrogen uric acid
creatinine calcium
glucose albumin
aspartate aminotransferase (AST) total protein
alanine aminotransferase (ALT)
gamma -glutamy ltransferase (GGT)
Urinaly sis(Dipstick)
specific gravity pH
-glucose protein
-blood ketone
-bilirubin urobilinogen
-nitrite leukocy te esterase
Specific gravity , pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen will be 
determined using a dipstick.
Female subjects must be post-menopausal with last menses 12 months prior, or longer, OR a 
measure d follicle stimulating hormone ≥26 mIU/mL .
Additional instructions relating to the clinical laboratory  tests are provided in the laboratory  
manual.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
55
Status: Approved , Date: 15 December 20179.5.3. Vital Signs 
Temperature, pulse/heart rate, respiratory  rate, blood pressure will be collected at the time points 
indicated in the Time and Events Schedule. Blood pressure and pulse rate measurements will be 
assessed sitting . Blood pressure and pulse rate measurements should be preceded by at least 
5minutes of rest in a quiet se tting without distractions (eg, television, cell phones).
9.5.4. Physical Examination
The study  investigator, or other authorized and appropriatel y qualified designee, will perform a 
targeted phy sical examination at the time points listed in the Time and Events Sc hedule.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the eCRF. Any clinicall y significant abnormalities persisting at the end of the 
study  or early  withdrawal will be followed by  the investigator until resolution or until a clinically  
stable endpoint is reached.
A targeted phy sical examination will be done at screening and at the 12 -monthly visit only .
9.6. Sample Collection and Handling
The actual dates and times of blood and urine sample collection must be recorded in the eCRF to 
the nearest minute ,or in laboratory  requisition form.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual. Collection, handling, storage, and shipment of samples must be according to 
specifications contained in the laboratory  manual.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Completion
A subject will be considered to have completed the 12-month acute phase of the study  if he or 
she has completed assessments at Month 12.Subjects who prematurel y withdraw for any reason 
before completion of the 12-month assessments will notbe considered to have completed the 
study .
A subject will be considered to have completed the Long-Term Follow -up Phase of the study  if 
he or she has completed assessments at Month 36 of the study .
10.2. Discontinuation/ Withdrawal from the Study
A subject should bewithdrawn from the study  if the investi gator believes that for safety  reasons 
(eg, an AE) it is in the best interest of the subject to discontinue.
If a subject discontinue sfrom the study  before the end of the 12- month acute phase, or before the 
end of the Long-term Follow -up Phase, end -of-studyassessments (Table 2 )should be performed . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
56
Status: Approved , Date: 15 December 2017In addition, if a subject undergoes surgery  but product is not administered, and the subject 
subsequently  discontinues from the study , the subject will be followed for safet y assessments .
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
If a subject is lost to follow -up, every reasonable effort must be made by  the study  site personnel 
to contact the subject and determine the reason for discontinuation/withdrawal. The measures 
taken to follow -up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source documen t. Subjects who withdraw will not be 
replaced. If a subject withdraws from the study ,end-of-st udyassessments (Table 2)should be 
performed .
Withdrawal from the Use of Sample s in Future Research
The subject may withdraw consent for use of sample sfor research (refer toSection 16.2.5 ,
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for research are presented in the main ICF and in the separate ICF for optional research 
samples.
11. STATISTICA L METHODS
Statistical analy sis will be done by the sponsor or under the authority  of the sponsor. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. In general, all data will be tabulated and display ed using descriptive methods only; no 
formal statistical testing is planned for outcome in the Safet y Cohort .
Analy ses will be conducted for all subjects who receive treatment in the open -label Safety
Run-in phase.
After the first 21 subjects participating in the open -label safety  run-in phase have completed 
1month of follow -up(the initial Safety  Cohort) , an analysis of data will be performed. These 
analyses will consist of simple descriptive statistics for key safety  and efficacy  measures, which 
will be described in the statistical analy sis plan ( SAP). 
11.1. Subject Information
For all subjects ,descriptive statistics of the baseline and demographic information by treatment 
group will be provided .
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
57
Status: Approved , Date: 15 December 2017Subject disposition will be summarized for subjects who recei ved cell injection . The number of 
subjects who discontinued study  participation early will be summarized by reason for 
discontinuation . A list of subjects who discontinued study  participation early will also be 
provided. The number of subjects with left or right treated ey e will be summarized. 
11.2. Sample Size Determination
The sample size of 21 subjects is based on the number of subjects require to allow for an 
adequate clinical assessment of the safety  and usability  of the novel delivery sy stem.
11.3. Efficacy  Analyses
The BCVA, LL BCVA, LLD, contrast sensitivity  and growth rate of GA lesion will be 
summarized with descriptive statistics as specified in the SAP.
11.4. Immunogenicity  Analyses
The incidence of antibodies to CNTO 2476 will be summarized for all subjects who receive a 
dose of CNTO 2476 and have appropriate samples for detection of antibodies to CNTO 2476
(ie,subjects with at least 1 sample obtained after their first dose of CNTO 2476).
11.5. Safety  Analyses
Safety  analyses will be performed for all subjects who receive treatment in the open -label Safety
Run-in phase .
Adverse Events
The verbatim terms used in the CRF by investigators to identify  AEs will be coded using the 
Medical Dictionary  for Regulatory  Activities (MedDRA). All reported AEs with onset from the 
surgery  start date and onwards (ie, treatment -emergent AEs, and AEs that have worsened since 
baseline) will be included in the anal ysis.
The number and percentage of subjects who experienced at least 1treatment -emergent serious 
ocular AEwill be presented in summary  tables by treatment group and preferred term according 
to MedDRA terminology as well as by  affected eyes (events occurring in the treated ey e only , in 
the fellow ey e only, and in both eyes). 
Ocular TEAEs will be summarized by treatment group and preferred term according to 
MedDRA terminology , as well as by affected eyes (events occurring in the treated eye only, in 
the fellow ey e only, and in both eyes). 
The number and percentage of subjects who experienced at least 1treatment- emergent SAE will 
be presented in summary tables by treatment group and preferred term, as well as by preferred 
term within sy stem -organ class according to MedDRA terminology . 
The number and percentage of subjects who experienced at least 1TEAE will be presented in 
summary  tables by treatment group and preferred term, as well as by preferred term within 
system -organ class according to MedDRA terminology . 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
58
Status: Approved , Date: 15 December 2017The following lists of individual subject data will also be provided: 
list of subjects with SAEs;
list of subjects with ocular AEs;
list of subjects who died while on study  (after administration ofCNTO 2476 cells);
list of subjects who discontinued the study  due to an AE;
list of subjects with TEAEs of severe intensity ;
list of subjects with TEAEs related to ey e surgery , surgical delivery  system, protocol-related 
procedure or CNTO 2476 cells;
list of subjects with treatment- emergent infections.
list of all AEs for subjects who have the surgical procedure but do not receive CNTO 2476 
cells.
Surgical Evaluation
Data regarding the Delivery  System and surgical procedure will be tabulated by treatment group.
A listing of all data pertaining to the Delivery  System and surgical procedure, as well as any 
surgical deviations will be provided.
Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Reference ranges will be used in 
the summary  of laboratory  data. Frequency  tabulations of the lab oratory results will be presented 
in pre-versus posttreatment cross -tabulations (with classes for below, within, and above normal 
ranges) by treatment group. Frequency  tabulations of the abnormalities by treatment group will 
also be made. A listing of subjects with any laboratory  results outside the reference ranges will 
be provided.
Descriptive statistics will be calculated for each laboratory  analyte at baseline and for observed 
values and changes from baseline at each scheduled time point by  treatment group.
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respiratory  rate, and blood pressure 
(systolic and diastolic) values and changes from baseline will be summarized at each scheduled 
time point by  treatment group. The percentage of subjects with values outside standard reference 
ranges will be summarized by treatment group. A listing of subjects with any vital signs results 
outside the standard re ference ranges will be provided.
11.6. Data and Safety Monitoring Board
A DSMB will be established to monitor data on an ongoing basis to ensure the continuing safety  
of the subjects enrolled in this study .The DSMB will consist of at least 1medical expert in the 
relevant therapeutic area, and at least 1statistician. The committee will meet periodicall y to 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
59
Status: Approved , Date: 15 December 2017review interim data. After the review, the DSMB will make recommendations regarding the 
continuation of the study .
The first formal safet y review will take place when 1 month safety  follow -up data are available 
for the 21subjects in the initial Safety  Cohort . In addition, the DSMB charter will specify  rules 
for interrupting the study  enrollment in the event of device -or procedure -related safet y events 
prior to the completion of the Safet y Cohort. Events of special interest are choroidal hemorrhage, 
endophthalmitis or infections, retinal detachments, leakage of cells into the vitreous/need for 
vitrectomy ,significant loss of vision defined as ≥15 letters lost compared to baseline (first month
post-surgery only),and failure to deliver cells/device failure.
Since no additional subjects are to be enrolled under this amendment, there will be no further 
DSMB meetings and DSMB will be disbanded; Janssen retains the option to reform the DSMB 
should the need arise.
The DSMB ’s responsibilities, authorities, and procedures, will be documented in a separate 
charter.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
relationship with the treatment. An AEcan therefore be any unfavorable and uninte nded sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investigational or non-investigational) product (definition per theInternational 
Conference on Harmonisation [I CH]) .
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF(refer to Section 12.3.1 , All 
Adverse Events, for time of last AErecording).
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
60
Status: Approved , Date: 15 December 2017Serious Adverse Event
AnSAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for 
Human Use is an y untoward medical occurrence that at any  dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent 1of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship between CNTO 2476, the delivery  system, or the device and the event, the event 
must be reported as a serious and unexpected suspected adverse reaction even if it is a 
component of the stud y endpoint.
Unlisted (Unexpected) Adverse Event/Reference Safet y Information
An AEis considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For CNTO 2476 , the expectedness of an AEwill be 
determined b y whether or not it is listed in the Investigator's Brochure.
Adverse Event Associated With the Use of the Drug
An AEis considered associated with the use of the drug if the attribution is possible, probable, or 
very likely by the def initions listed in Section 12.1.2 .
The surgical procedure and delivery  of CNTO 2476 result in a small retinal detach ment per 
procedure guidelines. This in itself should not be listed as an adverse event.
12.1.2. Attribution Definitions
Not Related
An AEthat is not related to the use of CNTO 247 6, or the Delivery  System.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
61
Status: Approved , Date: 15 December 2017Doubtful
An AEfor which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An AEthat might be due to the use of CNTO 2476 , or the Delivery  System . An alternative 
explanation, eg, concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in 
time is reasonable; therefore, the causal relationship cannot be excluded.
Probable
An AEthat might be due to the use of CNTO 2476 , or the Delivery  System . The relationship in 
time is suggestive. An alternative explanation is less likely , eg, concomitant drug(s), concomitant 
disease(s).
Very Likely
An AEthat is listed as a possible adverse reaction and cannot be reasonably  explained by an 
alternative explanation, eg, concomitant drug(s), concomitant disease(s). The relationship in time 
is very  suggestive .
12.1.3. Severity Criteria 
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety events of interest for CNTO 2476 that may require expedited reporting and/or safet y 
evaluation include, but are not limited to: 
Overdose 
Inadvertent or accidental exposure 
Medication error (with or without subject exposure to CNTO 2476, eg, name confusion)
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a SAE should be recorded on the SAE page of the CRF. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
62
Status: Approved , Date: 15 December 201712.3. Procedures
12.3.1. All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated ICFis obtained until completion of the subject's last study -related 
procedure (which may include contact for follow -up of safet y). Serious AEs, including those 
spontaneously reported to the investigator within 30 daysafter the last dose of CNTO 2476 , must 
be reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by an investigator beyond the time frame specified in 
the protocol.
All events that meet the definition of anSAE will be reported as SAE s, regardless of whether 
they are protocol -specific assessments. Anticipated events will be recorded and reported as 
described in Attachment 1.
All AEs, regardless of seriousness, severit y, or presumed relationship to treatment , must be 
recorded using medical terminology  in the source document and the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respiratory  
infection"). Investigators must record in the eCRF their opinion concerning the relationship of 
the AEto study  therap y. All measures required for AEmanagement must be recorded in the 
source document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate r eporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpected serious adverse reactions (SUSARS) . The investigator 
(or sponsor where required) must report SUSARS to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by  the IEC/IRB.
For all studies with an outpatient phase, including Open-label studies, the subject must be 
provided with a "wallet (study )card" and instructed to carry  this card with them for the duration 
of the study  indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name and 24-hour contact telephone number
Local sponsor's name and 24 -hour contact telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the mask.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
63
Status: Approved , Date: 15 December 201712.3.2. Serious A dverse Events
All SAEs occurring during thestudymust be reported to the appropriate sponsor contact person 
bystudy -site personnel within 24 hours of their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event 
Form, which must be completed and signed by  a physician from the study  site, and transmitted to 
the sponsor within 24 hours. The initial and follow -up reports of anSAE should be made by 
facsimile (fax) .
All SAEs that have not resolved by the end of the study , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the treatment or to factors unrelated to study 
conduct
It becomes unlikely  that any additional information can be obtained (subject orhealth care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow- up ef forts)
Suspected transmission of an infectious agent by the treatment will be reported as an SAE . Any 
event requiri ng hospitalization (or prolongation of hospitalization) that occurs during the course 
of a subject's participation in a study  must be reported as a SAE , except hospitalizations for the 
following:
Hospitalizations not intended to treat an acute illness or AE(eg, social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the 
eCRF ). Note: Hospitalizations that were planned before the signing of the ICF, and where 
the underlying condition for which the hospitalization was planned has not worsened ,will 
not be considered SAE s. Any AEthat results in a prolongation of the originall y planned 
hospitalization is to be reported as a new SAE .
The cause of death of a subject in a stud y within 30 day sof the last dose of CNTO 2476 , whether 
or not the event is expected or associated with CNTO 2476 , is considered an SAE .
12.4. Contacting Sponsor Regarding Safety
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed on the Contact Information 
page(s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
64
Status: Approved , Date: 15 December 201713. PRODUCT QUA LITY COMP LAINT HA NDLING
A product quality  complaint (PQC) is defined as any susp icion of a product /device defect related 
to manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product /device , including its labeling or package integrity . A PQC 
may have an impact on the safet y and efficacy of the product /device . Timely , accurate, and 
complete reporting and analy sis of PQC information from studies are crucial for the protection of 
subjects, investigators, and the sponsor , and are mandated b y regulatory  agencies worldwide. The 
sponsor has established procedures in conformity  with regulatory  requirements worldwide to 
ensure appropriate reporting of PQC information; all studies conducted by the sponsor or its 
affiliates will be conducted in accordance with those pro cedures.
The provisions for a PQC apply  to the CNTO 2476 product, as well as the Delivery  System.
13.1. Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with a SAE , the study -site personnel must report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 12.3.2 , Serious Adverse 
Events). A sample of the suspected product should be maintained for further investigation if 
requested b y the sponsor .
13.2. Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed on the Contact Information page(s), which will be 
provided as a separate document.
14. TREA TMENT INFORMA TION
14.1. Physical Description of CNTO 2476
CNTO 2476 is an allogeneic somatic cell therap y medicina l product derived from the isolation 
and ex vivo expansion of hUTC. I t is a cry opreserved cell suspension that is thawed immediatel y 
(within 2 hours) prior to administration to patients and read y for administration after thaw .
14.2. Packaging
CNTO 2476 supplied for this study  is manufactured and provided under the responsibility  of the 
sponsor . CNT O 2476 cryopreserved drug product (CDP) is a cell suspension formulated in 
chemicall ydefined freezing medium containing CryoStor™ -SCO 4B (custom formulation) and 
Balanced Salt Solution®(BSS) Sterile Irrigating Solution. CNTO 2476 is filled in Crystal 
Zenith®resin vials and stored at < −120ºC. Each single -usevial contains 330 μL of cell 
suspension of which 50 μL will be administered. The overfill is required to transfer and fill the 
Delivery  System. Thecells will be administered in the subretinal space of the eye using the
Delivery  System.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
65
Status: Approved , Date: 15 December 2017Each vial is enclosed in a paperboard carton with appropriate labeling on the carton.
14.3. Labeling
Treatment labels will con tain information to meet the applicable regulatory  requirements.
14.4. Preparation, Handling and Storage
Each site will be provided with an Investigational Product Manual with detail edinstructions for 
proper preparation, handling and storage of CNTO 2476.
CNTO 2476 must be stored at controlled temperatures ranging from −321°F to −184°F ( −196°C to 
−120°C). CNTO 2476 is shipped to the clinical site in a liquid nitrogen vapor -phase shipper that is 
also used for short -term storage up to 7calendar days after shipment. The distribution is on a just-
in-time basis for each treatment in the trial. The shipment for a subject will be triggered when 
enrolled or randomized through the I WRS.
At the time of surgery , CNTO 2476 will be thawed in a controlled manner per the instruction sin 
the Investigational Product Manual.
14.5. Investigational Product and Device Accountability
The investigator is responsible for ensuring that all CNTO 2476 ,Delivery  System devices
received at the site are inventoried and accounted for throughout the study , per the requirements 
in the Investigational Product Manual . All CNTO 2476 will be stored and disposed of according 
to the sponsor's instructions, per the Investigational Product Manual. Study -site personnel must 
not comb ine contents of the CNTO 2476 containers.
15. STUDY -SPECIFIC MATERIA LS
The following will be provided to the investigator/clinical site as reference materials :
Investigator Brochure
Ophthalmic Examination Manual s
Investigational Product M anual
Study  Manual
Laboratory  Manual
PRO questionnaires (NEI-VFQ -25,SF-36, and FRI )
IWRS Manual
eDC Manual
Sample I CF
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
66
Status: Approved , Date: 15 December 201716. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Age-related macular degeneration is a debilitating and common cause of blindness in persons over 
60 years of age. For GA, the severe dryform of AMD, there is no approved therapy . Preliminar y 
clinical data suggests that CNTO 2476 may  improve visual acuit y in patients with GA.
The primary  risk is related to the novel delivery  procedure and subretinal access ki t; there may  also 
be risk associated with the cell therapy . For this reason, the study  is designed with an open -label 
Safet y Run-in Phase andSafet y Cohort to ensure safety of the surgical procedure prior to the 
randomized portion of the study ; an independ ent DSMB will provide oversight through the first 
12months of the study . Extensive training for proper use of the subretinal access kit will be 
provided to all surgeons, and all procedures will be monitored by  representatives of the sponsor.
In addition t o adherence to Good Clinical Practices ( GCPs) , the study  will also follow Good Tissue 
Practices (GTPs) to maximize and manage the safety  of injected human cells. Subjects will be 
asked to be followed for up to 36months to assess the long-term safety  outcomes of the cell 
therapy .
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential AEs of the study , and provide their consent voluntaril y will be enrolled. Consent will be 
provided in a format thatis accessible to subjects with severe visual impairment.
The total blood volume to be collected isapproximatel y107.4 mL, and is considered to bewithin 
the normal range allowed for this subject population over the time period (3years) proposed for 
this study , and is within the range of Red Cross blood donations.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibili ties
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on GCP, GTP, and applicable regulatory  and country -specific 
requirements.
Good Clinical Practice is an international ethic al and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjec ts are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
67
Status: Approved , Date: 15 December 201716.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copies of the following documents (as required by local 
regulations) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to t he subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicabl e
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjec ts
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct ), the ICF, applicable recruiting materials, and 
subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB andthe documents being 
approved.
Approval for the collection of optional samples for research and for the corresponding ICFmust 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component . 
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequenc es for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries orpayment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the treatment
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
68
Status: Approved , Date: 15 December 2017New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazar ds to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC /IRB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/IRB will be asked to review and reapprove this study . The 
reapproval should be documented in writing (excluding the ones that are purel y administrative, 
with no consequences for subjects, data, or stud y conduct) .
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before performance of any 
study -related activity . The ICF(s) that is/areused must be approved by both the sponsor and by 
the reviewing IEC/I RB and be in a language that the subject can read and understand. The 
informed consent should be in accordance with principles that originated in the Declaration of 
Helsinki, current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor 
policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate wil l not 
affect the care the subject will receive. Finally , they will be told that the investigator will 
maintain a subject identification register for the purposes of long-term follow -up if needed and 
that their records may be accessed by health authorities and authorized sponsor personnel
without violating the confidentiality  of the subject, to the extent permitted by the applicable 
law(s) or regulations. By signing the ICFthe subject is authorizing such access, including 
permission to obtain information about his or her survival status, and agrees to allow his or her 
study  physician to recontact the subject for the purpose of obtaining consent for additional safety 
evaluations, if needed, and subsequent disease -related treatments, or to obtain information about 
his or her survival status.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
69
Status: Approved , Date: 15 December 2017The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by means of the subject's per sonall y dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Subjects will be asked for consent to provide optional samples for research where local 
regulations permit. After informed consent for the study  is appropriatel y obtained, the subject 
will be asked to sign and personall y date a separate ICFindicating agreement to participate in the 
optional research component . Refusal to participate in the optional research will not result in 
ineligibility  for the stud y.A cop y of this signed ICF will be given to the subject.
If the subject is unable to read or write, an impartial witness should be present for the entire 
informed consent process (which includes reading and explaining all written information) and 
should personally  date and sign the ICFafter the oral consent of the subject is obtained.
All study  sites will be asked by the sponsor to obtain informed consent using a validated 
electronic system instead of a pape r-based process. If both parties (sponsor and the study  site) 
agree, and if participation is allowed by local regulations and IEC/IRB requirements, the means 
to facilitate such a process will be provided to the sites by sponsor. The actual mechanism of 
consenting will be facilitated by  the use of an eTablet device (eg, iPad®), but overall the consent 
process will remain the same, as described in this section. At these study  sites, subjects will still 
be required to review the entire informed consent as a written document on the eTablet and then 
to apply  their handwritten signature electronicall y by the use of a st ylus directly  onto the eTablet. 
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/documents) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the r ight to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the natu re of the request, the 
conditions of the study , and the applicable laws and regulations.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
70
Status: Approved , Date: 15 December 2017Exploratory  DNA and immunogenicit y research is not conducted under standards appropriate for 
the return of data to subjects. In addition, the sponsor cannot make decis ions as to the 
significance of any findings resulting from exploratory  research. Therefore, exploratory  research 
data will not be returned to subjects or investigators, unless required by lawor local regulations . 
Privacy  and confidentiality  of data genera ted in the future on stored samples will be protected by  
the same standards applicable to all other clinical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research 
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand CNTO 2476 , to 
understand visual acuit y impairment associated with GA secondary  to AMD ,to understand 
differential responders, and to develop tests/assays related to CNTO 2476 and visual acuit y 
impairment associated with GAsecondary  to AMD .The research may begin at any time during 
the study  or the post -study  storage period.
Stored sampl es will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study , the 
IRB (and IEC where required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page [s]provided separa tely). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course of action. The data recorded in the CRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
71
Status: Approved , Date: 15 December 201717.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of CNT O 2476 and 
Delivery  Systemto the study site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by titleand number and must be signed (or sealed, where appropriate per local 
regulations) by the chairman or authorized designee.
Name and address of the IEC/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study -sitepersonnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial ag reement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from al l subinvestigators
Documentation of subinvestigator qualifications (eg, curriculum vitae)
Name and address of any local laboratory  conducting tests for the study , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
72
Status: Approved , Date: 15 December 201717.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to perm it easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor study -site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by subject identification
and date of birth. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility for inclusion in the study .
17.4. Source Documentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the CRF: subject identification, eligibility , and study  identification; study  discussion 
and date of signe d informed consent; dates of visits; results of safety  and efficacy  parameters as 
required by the protocol; record of all AEs and follow -up of AEs; concomitant medication; 
CNTO 2476 and devise receipt/dispensing/return records; treatment administration information ; 
and date of study  completion and reason for early  discontinuation of study drug or withdrawal 
from the study , if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document).
The following data will be recorded directl y into the CRF and will be considered source data:
Demographics
History  of smoking
Blood pressure and pulse/heart rate
Height and weight
Details of ph ysical examination
Patient Reported O utcomes
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2, Exclusion Criteria that specify  a need for documented medical history  are as 
follows:
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
73
Status: Approved , Date: 15 December 2017Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by subject intervi ew or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
17.5. Case Report Form Completion
Case report forms are provided for each subject in an electronic format. 
Electronic Data Capture (eDC) will be used for this study . The study  data will be transcribed by 
study -sitepersonnel from the source documents onto an electronic eCRF, and transmitted in a 
secure manner to the sponsor within the timeframe agreed upon between the sponsor and the 
study  site. The electronic file will be considered to be the eCRF.
Worksheets and intraoperative videos may be used for the capture of some data to facilitate 
completion of the eCRF (ie,data collection during cell delivery  procedure) .Any such worksheets 
and videos will become part of the subject's source documentation. All data relating to the study 
must be recorded in CRFs prepared by the sponsor . Data must be entered into CRFs in English.
Study site personnel must complete the CRF as soon as possible after a subject visit, and the 
forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, PROquestionnaires) will be completed by the same individual 
who made the initial baseline determinations whenever possible. The investigator must verify
that all data entries in the CRF s are accurate and correct.
All CRF entries, corrections, and alteratio ns must be made b y the investigator or other authorized 
study -site personnel. If necessary , queries will be generated in the eDC tool.
If corrections to a CRF are needed after the initial entry  into the CRF, this can be done in 
3different way s:
Study site personnel can make corrections in the eDC tool at their own initiative or as a 
response to an auto query (generated b y the eDC tool) .
Study site manager can generate a query  for resolution by  the study -site personnel.
Clinical data manager can generate a query  for resolution by  the study -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol p rocedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by the sponsor , and direct 
transmission of clinical laboratory  data from a central laboratory and all outside vendors into the 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
74
Status: Approved , Date: 15 December 2017study  database into the sponsor's data base. Written instructions will be provided for collection, 
handling, storage, and shipment of samples.
Guidelines for eCRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the study .The sponsor will review eCRFs for accuracy  and completeness during 
on-site monitoring visits and after transmission to the sponsor; any  discrepancies will be resolved 
with the investigator or designee, as appropriate. After upload of the data into the study database 
they will be verified for accuracy  and consistency  with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8 , Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applicatio ns in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investig ator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor /designee will perform on-site monitoring visits as frequently  as necessary . The 
monitor will record dates of the visits in a study  site visit log that will be kept at the study  site.
The first post-initiation visit will be made as soon as possible after enrollment has begun. At 
these visits, the monitor will compare the data entered into the eCRFs with the hospital or clinic 
records (source documents). The nature and location of all source documents will be identified to 
ensure that all sources of original data required to complete the eCRF are known to the sponsor 
and study -site personnel and are accessible for verification by the sponsor study -site contact. If 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
75
Status: Approved , Date: 15 December 2017electronic records are maintained at the study site, the method of verification must be discussed 
with the study -site personnel .
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the CRF are consistent with the original source data. Findings 
from this review of CRFs and source documents will be discussed with the study -site personnel. 
The sponsor expects that, during monitoring visits, the relevant study -site personnel will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study to provide feedback on the study conduct.
Thesponsor will cond uct on-site monitoring and support on Day 1 of the study , and throughout 
the surgical procedure . Representatives from the sponsor compan y, Janssen and/or its designees 
may be present at the clinical facility , in the operating room during surgery  or observi ng 
remotely . This is to ensure oversight of aspects of the surgical procedure and protocol .
17.9. Study Completion/Termination
17.9.1. Study Completion
The study  is considered completed with the last study  assessment for the last subject 
participating in the study . The final data from the study site will be sent to the sponsor (or 
designee) after completion of the final subject assessment at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the i ntended termination.
Reasons for the earlyclosure of astudy site by the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further treatment development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
76
Status: Approved , Date: 15 December 2017with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection and comparison with the CRFs. Subject 
privacy  must, however, be respected. The investigator and study -site personnel are responsible 
for being present and available for consultation during routinely  scheduled study -site audit visits 
conducted b y the sponsor or its designees.
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immedi ately  notify  the sponsor if he or shehas
been contacted b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding CNTO 2476 or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by the sponsor to the investigator and not 
previously  published, and any data, including pharmacogenomic or explorat ory research data, 
generated as a result of this study , areconsidered confidential and remain the sole propert y of the 
sponsor. The investigator agrees to maintain this information in confidence and use this 
information only to accomplish this study , and will not use it for other purposes without the 
sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by the 
sponsor in connection with the continued development of CNTO 2476 , and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor with all data obtained in the study .
The results ofthe study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain CRF data from all study  sites that participated in the study , and direct transmission 
of clinical laboratory  data from a central laboratory  into the sponsor's database. Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of pharmacogenomic or 
exploratory  analyses performed after the Clinical Study  Report has been issued will be reported 
in a separate report and will not require a revision of the Clinical Study Report. Study  subject 
identifiers will not be used in publication o f results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by the investigator as provided for below) shall be the propert y of the 
sponsor as author and owner of cop yright in such work.
Consistent with Good Publica tion Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy  of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presen tation. Expedited reviews will be 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
77
Status: Approved , Date: 15 December 2017arranged for abstracts, poster presentations, or other materials. If requested by the sponsor in 
writing, the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the primary  endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicente r study by not submitting for publication 
data derived from the individual study  site until the combined results from the completed study
have been submitted for publication, within 12 months of the availability  of the final data (tables, 
listings, graphs) , or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and/or disclose the existence of and the results of clinical studies as 
required b y law.
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
78
Status: Approved , Date: 15 December 2017REFERENCES
1. Allikmets R, Singh N, Sun H, et al . A photoreceptor cell -specific ATP-binding transporter gene (ABCR) is 
mutated in recessive Stargardt macular dystrophy. Nat Genet. 1997;15:236 -246. 
2. Cuenca N, Pinilla I, Sauve Y, Lund R. Early changes in synaptic connectivity following progressive 
photoreceptor degeneration in RCS rats. Eur J Neurosci. 2005;22:1057 -1072. 
3. de Jong P T. Age -related macular degeneration. N Engl J Med. 2006;355:1474 -1485. 
4. Fujihara M, Nagai N, Sussan TE, Bisw al S, Handa JT. Chronic cigarette smoke causes oxidative damage and 
apoptosis to retinal pigmented epi thelial cells in mice. PLoS ONE. 2008;3:e3119. 
5. Gal A, Li Y, Thompson DA, et al. Mutations in MERTK, the human orthologue of the RCS rat retinal 
dystrophy gene, cause retinitis pigmentosa. Nat Genet. 2000; 26:270-271. 
6. Glotin AL, Debacq -Chainiaux F, Brossas JY, Faussat AM, Treton J, Zubielewicz A, et al. Prem aturely 
senescent ARPE -19 cells display features of age -related macular degeneration. Free Radic Biol Med. 
2008;44:1348 -1361. 
7. Investigator’s Brochure : CNTO 2476, Edition 9, 2013
8. Johnson PT, Brown MN, Pu lliam  BC, Anderson DH, Johnson LV. Synaptic pathology, altered gene 
expression, and degeneration in photoreceptors impacted by drusen. Invest Ophthalmol Vis Sci. 
2005;46:4788 -4795. 
9. Liang FQ, Godley BF . Oxidative stress -induced mitochondrial DNA damage in human retinal pigment 
epithelial cells: a possible mechanism for RPE aging and age -related macular degeneration. Exp Eye Res. 
2003;76:397 –403. 
10. Lindblad AS, Clemons TE. Responsiveness of the National Eye Institute Visual Function Questionnaire to 
progressi on to advanced age-related macular degeneration, vision loss, and lens opacity : AREDS Report no. 
14. Arch Ophthalmol. 2005;123:1207 -1214. 
11. Liu J, Itagaki Y, Ben -Shabat S, Nakanishi K, Sparrow  JR. The biosynthesis of A2E, a fluorophore of a ging 
retina, involves the formation of the precursor , A2-PE, in the photoreceptor outer segment membrane. J Biol 
Chem. 2000:275;29354 –29360. 
12. Now ak JZ. Age -related macular degeneration (AMD): pathogenesis and therapy. Pharmacol Rep. 
2006;58:353 -363. 
13. Strauss O.The ret inal pigment epithelium in visual function. Physiol Rev. 2005;85:845 -881. 
14. Strauss O, Stumpff F, Mergler S, Wienrich M, Wiederholt M. The Royal College of Surgeons rat: an animal 
model for inherited retinal degeneration with a still unknown genetic defect. Acta Anat (Basel).
1998;162:101 -111. 
15. Sullivan RK, Woldemussie E, Pow  DV. Dendritic and synaptic plasticity of neurons in the human age -related 
macular degeneration retina. Invest Ophthalmol Vis Sci. 2007 Jun;48:2782 -2791. 
16. The Eye Diseases Prevalence Research Group. Prevalence of Age -Related Macular Degeneration in the United 
States. Arch Ophthalmol. 2004;122:564 -572. 
17. Virzi RA. Refining the test phase of usability evaluation; how many subjects is enough? Human Factors. 
1992;34:457 -468. 
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
79
Status: Approved , Date: 15 December 2017Attachment 1:Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non -serious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease related) or background regimen.
For the purposes of this study the following events will be considered anticipated events: 
 Fatal and non- fatal myocardial infarction
 Angina pectoris
 Fatal and non- fatal stroke
 Transient ischemic attack
 Chronic obstructive pulmonary disease (COPD), COPD exacerbation and chronic bronchitis
Reporting of Anticipated Events
These events will be captu red on the CRF and in the database, and will be reported to the sponsor as 
described in Section 12.3.1 , All adverse event s. Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2, Serious 
Adverse Events . These anticipat ed events are exempt from expedited reporting as individual single cases 
to Health Authorities. However ,if based on an aggregate review, it is determined that an anticipated event 
is possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-specified 
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Ana lysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
[STUDY_ID_REMOVED]
CNTO 2476
Clinical Protocol CNTO2476MDG2002 Amendment 3
80
Status: Approved , Date: 15 December 2017INVESTIG ATOR AGREEMENT
[STUDY_ID_REMOVED]